

## In Brief

The use of vitamin, mineral, and other complementary nutrition-based therapies has increased dramatically in the United States. Many health care providers are also beginning to explore the use of these therapies in their practices. For those of us who work in conventional health care settings, this is a new venture. But for many of our patients who have been self-medicating with supplements, it is not. This article reviews how micronutrient requirements are determined and summarizes current recommendations for supplementation and the most pertinent research on the use of key vitamins and minerals in diabetes management.

## Select Vitamins and Minerals in the Management of Diabetes

Belinda S. O'Connell, MS, RD, LD

Vitamins and minerals play diverse roles in our bodies. Initially, the nutrition community focused on the roles micronutrients play in preventing deficiency diseases such as scurvy, pellagra, and rickets. As our understanding of nutritional science grew, it became clear that nutrients act in far broader ways. We now know that micronutrients can regulate metabolism and gene expression and influence the development and progression of many chronic diseases.<sup>1</sup> Eventually, we may be able to tailor nutritional recommendations to individuals' unique genetic makeup, thus increasing the potential benefit and positive outcomes of medical nutrition therapy.

### MICRONUTRIENTS

Micronutrients are vitamins and minerals that our bodies require in small quantities for specific functions. They most commonly function as essential coenzymes and cofactors for metabolic reactions and thus help support basic cellular reactions (i.e., glycolysis, the citric acid cycle, lipid and amino acid metabolism) required to maintain energy production and life.<sup>1</sup> Even moderate deficiencies can lead to serious disease states. Micronutrients have been investigated as potential preventive and treatment agents for both type 1 and type 2 diabetes and for common complications of diabetes.<sup>2,3</sup>

Micronutrient requirements can be difficult to determine because many noninvasive assessment methods, such as the measurement of plasma nutri-

ent levels, do not accurately reflect the quantities of nutrients present in functionally important nutrient pools, and many dietary assessment methods and databases are not perfectly accurate.<sup>1-4</sup>

These and other methodological concerns have limited researchers' ability to conduct well-designed, targeted studies of micronutrient supplements in individuals who are deficient and therefore most likely to benefit from supplementation. This has likely contributed to the varied results obtained in research studies of micronutrients in people with diabetes.

Other research variables that may also contribute to the lack of consensus in study results include the use of diverse populations of patients with diabetes stemming from different biochemical origins, differences in glycemic control, variations in doses and forms of micronutrients used, variable study length, lack of control for dietary contribution of micronutrients, and use of different biochemical assays and methods of analysis.<sup>1-4</sup> We are unlikely to have conclusive data until these methodological concerns are resolved.

The American Diabetes Association (ADA) and the American Dietetic Association recommend that healthy people at low risk for nutritional deficiencies meet their nutritional requirements with natural food sources. These organizations do not generally support the use of micronutrient supplements for people with diabetes, and the supplements they do recom-

mend are the same as those recommended for the general public. The ADA does note that people who are at increased risk for micronutrient deficiencies, such as those following very-low-calorie diets, the elderly, strict vegetarians, and other special populations, may benefit from multivitamin supplements.<sup>2,3</sup>

Current nutritional guidelines are based on Dietary Reference Intakes (DRIs). DRIs, established in 1998, expand on the previously used Recommended Dietary Allowances (RDAs). DRIs are composed of four values: the RDA, the Adequate Intake (AI), the Estimated Average Requirement (EAR), and the Tolerable Upper Intake Level (UL).

The RDA is the level of nutrient intake believed to meet the needs of nearly all healthy individuals. It is most appropriately used as a target intake goal. However, intakes that fall below the RDA are not necessarily deficient because the RDA, by definition, is significantly greater than the needs of many people. The AI is used in place of the RDA for nutrients for which we do not yet have sufficient scientific evidence to establish an RDA.

The EAR is the level of nutrient intake believed to meet the requirements of half of the healthy individuals in a given life stage or gender group. It is most appropriately used to assess the likelihood of a nutritional deficiency. Diets that fall below the EAR for a given nutrient have a  $\geq 50\%$  chance of being inadequate. Supporting clinical and biochemical evidence is needed to establish the presence of an actual deficiency.

The UL is the greatest level of nutrient intake for which no adverse side effects have been noted. It is based on the members of a healthy population who are most likely to experience toxicity. The UL is usually based on total daily nutrient intake from both food and supplements. It is most appropriately used to assess the level of chronic daily nutrient intake that is likely to cause significant negative side effects. (For more information on DRIs, visit the National Institutes of Health Office of Dietary Supplements Website: <http://odp.od.nih.gov/ods>. Full text of all the DRI documents can be accessed without charge from the National Academy Press Website: [www.nap.edu](http://www.nap.edu).)

Vitamin and mineral supplements are regulated by the Food and Drug

Administration under the 1994 Dietary Supplement Health and Education Act (DSHEA). This act provides for only minimal regulatory oversight of supplement manufacturing and processing, focusing instead on the labeling and marketing of these products.

## SELECT MICRONUTRIENTS IN DIABETES MANAGEMENT

### Chromium

The trace element trivalent chromium (Cr+3) is required for the maintenance of normal glucose metabolism. Experimental chromium deficiency leads to impaired glucose tolerance, which improves upon the addition of chromium to the diet.<sup>5</sup> Because there is no accurate biochemical indicator of chromium status, the determination of clinical chromium deficiency is difficult.<sup>2,5</sup> Effects of chromium on glycemic control, dyslipidemia, weight loss, body composition, and bone density have all been studied.<sup>4,5</sup>

The current AI for chromium is 25  $\mu\text{g}$  for women and 35  $\mu\text{g}$  for men. No UL has been established. Previous recommendations placed a daily intake of  $\leq 200$   $\mu\text{g}/\text{day}$  within a safe and adequate range. Usual dietary intakes in the United States are estimated to range between 20 and 30  $\mu\text{g}/\text{day}$ .<sup>5</sup>

There is no evidence that people with diabetes have increased rates of deficiency, although several risk factors for micronutrient deficiencies are common in people with diabetes. These include hyperglycemia and glycosuria, low-calorie diets, and increased age. Other factors that may increase chromium requirements include pregnancy, lactation, stress, infection, physical trauma, and chronic vigorous exercise.<sup>4,5</sup> Because chromium is a nutrient, supplements will only benefit individuals who have a deficiency.

**Mechanism of action.** Chromium appears to act by enhancing or potentiating insulin's actions.<sup>6</sup> No chromium-containing enzyme has been discovered, and the biologically active form of chromium is still uncertain. Chromium's actions have been attributed to an increase in the number of insulin receptors,<sup>5</sup> increased binding of insulin to the insulin receptor, and increased activation of the insulin receptor in the presence of insulin.<sup>6</sup> In vitro studies using organic forms of chromium have documented altered activity of phosphotyrosine phosphatase and phosphotyrosine kinase.<sup>5,6</sup>

**Evidence-based research.** Numerous researchers have investigated the effects of chromium supplements on glycemic control in type 2 diabetes,<sup>7-13</sup> type 1 diabetes,<sup>8</sup> gestational diabetes,<sup>14</sup> insulin resistance,<sup>15</sup> reactive hypoglycemia,<sup>16</sup> the elderly,<sup>17</sup> and steroid-induced diabetes.<sup>18</sup> Chromium has also been shown to improve various aspects of dyslipidemia in diabetic subjects.<sup>7,9,10</sup> There are few well-controlled, well-designed studies.

The most definitive support for chromium supplementation in type 2 diabetes was provided by a 1997 randomized, double-blind, placebo-controlled study conducted in China by Anderson et al.<sup>7</sup> One hundred and eighty subjects were randomized to placebo, 200  $\mu\text{g}/\text{chromium picolinate}/\text{day}$ , or 1,000  $\mu\text{g}$  chromium picolinate/day for 4 months. HbA<sub>1c</sub> significantly declined in both groups at 4 months compared to placebo ( $P < 0.05$ ) (placebo 8.5%, 200  $\mu\text{g}$  7.5%, 1,000  $\mu\text{g}$  6.6%). Fasting blood glucose (FBG) levels, 2-h oral glucose tolerance test, and insulin and cholesterol levels all decreased in the high-dose-supplement group at 4 months.

The dose-dependent response and clinically significant decreases in HbA<sub>1c</sub> (decreases are similar in magnitude to those seen with many oral hypoglycemic agents) seen in this study are encouraging, although questions remain about its applicability in the United States, where ethnicity, dietary chromium intakes, and average body mass index of people with diabetes differ from those of the Chinese subjects.

Overall, the results of research studies are mixed,<sup>5</sup> with some showing positive effects<sup>7,8,10-14</sup> and others having clearly negative or ambiguous results.<sup>9,10,16,18</sup> Studies using higher doses<sup>7,11,12</sup> and more bioavailable forms of chromium<sup>7,8,11-13</sup> have had more positive effects than those using other forms of chromium.<sup>10,16,18</sup> Studies in which subjects were possibly consuming low-chromium diets or had other risk factors for deficiency were also more likely to show positive effects.<sup>7,11,13,14</sup>

Research on chromium is summarized in Table 1. When evaluating these studies, one must pay particular attention to the form and dose of chromium used; the etiology of diabetes in the population studied; subjects' duration of diabetes, ethnicity, and weight; study duration; subjects' relative glycemic control; statistical

Table 1. Select Chromium Clinical Trials

Ref.	Subjects	Design	Results	Notes
7	<ul style="list-style-type: none"> <li>• 180 type 2</li> <li>• BMI 25</li> <li>• China</li> <li>• O, I, D</li> <li>• HbA<sub>1c</sub> 9–12%</li> </ul>	<ul style="list-style-type: none"> <li>• RDBPCT</li> <li>• Cr picolinate</li> <li>• 200 or 1,000 µg/day</li> <li>• 4 months</li> </ul>	<ul style="list-style-type: none"> <li>• FBG decreased (<math>P &lt; 0.05</math>) at 4 months in the 1,000-µg group</li> <li>• HbA<sub>1c</sub> decreased at 2 and 4 months in the 1,000-µg group, at 4 months in the 200-µg group (placebo 8.5%, 200 µg 7.5%, 1,000 µg 6.6%, <math>P &lt; 0.05\%</math>)</li> <li>• OGTT: 2-h glucose decreased in 1,000-µg group (<math>P &lt; 0.05</math>); fasting, 2-h insulin decreased (<math>P &lt; 0.05</math>) in both groups</li> <li>• Cholesterol levels decreased in the 1,000-µg group (<math>P &lt; 0.05</math>)</li> </ul>	<ul style="list-style-type: none"> <li>• Low BMI</li> <li>• Clinically significant results</li> <li>• Dose-dependent response</li> <li>• Ethnicity</li> <li>• Dietary Cr and initial Cr status unknown</li> </ul>
12	<ul style="list-style-type: none"> <li>• 833 type 2</li> <li>• China</li> <li>• O, I</li> </ul>	<ul style="list-style-type: none"> <li>• Up to 10 months</li> <li>• Non-placebo-controlled follow-up</li> <li>• 500 µg/day</li> <li>• Cr picolinate</li> </ul>	<ul style="list-style-type: none"> <li>• FBG decreased from 10.0 to 8.0 mmol/l</li> <li>• Postprandial BG improved from 12.0 to 9.9 mmol/l</li> <li>• 391 of 443 subjects who had reported symptoms of fatigue reported improvement; 287 of 334 reported improvement in symptoms of thirst; and 282 of 322 reported a decrease in incidence of frequent urination</li> </ul>	<ul style="list-style-type: none"> <li>• Effects were similar after 1–10 months.</li> <li>• Similar effects in men and women</li> <li>• No confirmed negative side effects of supplemental Cr</li> <li>• Average BMI of subjects unknown</li> </ul>
11	<ul style="list-style-type: none"> <li>• 29</li> <li>• Positive family history</li> <li>• Obese</li> <li>• BMI 33–34</li> <li>• Age ~45 years</li> </ul>	<ul style="list-style-type: none"> <li>• RDBPCT</li> <li>• 1,000 µg/day</li> <li>• Cr picolinate</li> <li>• 8 months</li> </ul>	<ul style="list-style-type: none"> <li>• Cr improved insulin sensitivity per FSIVGTT (40%) (<math>P &lt; 0.005</math>)</li> <li>• No change in HbA<sub>1c</sub> or fructosamine</li> </ul>	<ul style="list-style-type: none"> <li>• Increased risk of diabetes</li> <li>• &gt;125% IBW</li> <li>• 3-day food records to assess usual diet</li> <li>• Meals for 2 days before FSIVGTT provided</li> </ul>
13	<ul style="list-style-type: none"> <li>• 30 GDM</li> <li>• Age 25–43 years</li> <li>• D, I</li> </ul>	<ul style="list-style-type: none"> <li>• DBPCT</li> <li>• 4 µg/kg/day, placebo, 8 µg/kg/day</li> <li>• Cr picolinate</li> <li>• 8 weeks</li> </ul>	<ul style="list-style-type: none"> <li>• 4 µg/kg/day Cr group had decreased HbA<sub>1c</sub> from 5.6 to 5.2% (<math>P &lt; 0.05</math>); no change in placebo or 8 µg/kg/day Cr group</li> <li>• 4 µg/kg/day Cr group had decreased fasting insulin (<math>P &lt; 0.035</math>) and C-peptide (<math>P &lt; 0.044</math>) and decreased postprandial BG (<math>P &lt; 0.049</math>), insulin (<math>P &lt; 0.005</math>), and C-peptide (<math>P &lt; 0.033</math>)</li> <li>• 8 µg/kg/day Cr group had decreased fasting insulin (<math>P &lt; 0.007</math>) and decreased postprandial BG (<math>P &lt; 0.007</math>), insulin (<math>P &lt; 0.049</math>), and C-peptide (<math>P &lt; 0.011</math>)</li> </ul>	<ul style="list-style-type: none"> <li>• Week 20–24 of gestation</li> <li>• Only partial randomization</li> <li>• 4 µg/kg/day group had higher initial HbA<sub>1c</sub>: 5.6% versus 4.7% in placebo group and 5.1% in 8 µg/kg/day group.</li> <li>• No comment on statistical significance of differences</li> <li>• Average BMI of study subjects unknown</li> </ul>
10	<ul style="list-style-type: none"> <li>• 25 type 2</li> <li>• 51 CVD only</li> <li>• Age 63.6 years</li> <li>• D, O</li> </ul>	<ul style="list-style-type: none"> <li>• RDBPCT</li> <li>• 250 µg/day</li> <li>• Cr chloride</li> <li>• 7–16 months; mean 11 months</li> </ul>	<ul style="list-style-type: none"> <li>• No change in FBG</li> <li>• No change in cholesterol</li> <li>• Decrease of TG (<math>P &lt; 0.02</math>) and VLDL (<math>P &lt; 0.05</math>) and increase in HDL (<math>P &lt; 0.005</math>) in Cr group</li> </ul>	<ul style="list-style-type: none"> <li>• Subjects all with established CVD-MI or intermittent claudication</li> <li>• No adverse effects; no change in weight</li> <li>• HbA<sub>1c</sub> of diabetic subjects not reported</li> </ul>
16	<ul style="list-style-type: none"> <li>• 24 IGT</li> <li>• Age 65–74 years</li> <li>• BMI 30</li> <li>• Finnish</li> </ul>	<ul style="list-style-type: none"> <li>• DBPCT</li> <li>• 6 months</li> <li>• 160 µg/day</li> <li>• Cr-rich yeast</li> </ul>	<ul style="list-style-type: none"> <li>• BMI decreased in Cr group (<math>P &lt; 0.05</math>)</li> <li>• No significant changes in HbA<sub>1c</sub>, FBG, fasting insulin levels, 1- or 2-h postprandial insulin, or BG levels in Cr group</li> <li>• No significant changes in lipoprotein levels</li> </ul>	<ul style="list-style-type: none"> <li>• Trend to lower postprandial insulin levels in Cr group attributed to weight loss</li> </ul>
9	<ul style="list-style-type: none"> <li>• 28 type 2</li> <li>• D, O, I</li> <li>• Age 56 years</li> <li>• BMI 31.2</li> </ul>	<ul style="list-style-type: none"> <li>• RDBPCT cross-over</li> <li>• 2 months Cr</li> <li>• 2 months washout</li> <li>• 200 µg/day</li> <li>• Cr picolinate</li> </ul>	<ul style="list-style-type: none"> <li>• No significant change in FBG, HbA<sub>1c</sub>, LDL, or HDL levels in either treatment</li> <li>• TG levels decreased 17.4% from 161 to 133 mg/dl (<math>P &lt; 0.05</math>)</li> </ul>	<ul style="list-style-type: none"> <li>• No adverse effects of Cr</li> <li>• All but two subjects had undetectable serum Cr levels at start</li> <li>• TG not particularly high to start with</li> <li>• Community primarily Hispanic</li> </ul>

BG, blood glucose; Cr, Chromium; CVD, cardiovascular disease; D, use of medical nutrition or diet therapy; DBPCT, double-blind, placebo-controlled trial; FSIVGTT, frequently sampled intravenous glucose tolerance test; GDM, gestational diabetes mellitus; I, use of insulin; IBW, ideal body weight; IGT, impaired glucose tolerance; MI, myocardial infarction; O, use of oral diabetes medication; OGTT, oral glucose tolerance test; RDBPCT, randomized, double-blind, placebo-controlled trial; TG, triglycerides.

and clinical relevance of the data; and the study design (with randomized, double-blind, placebo-controlled studies that control for dietary intake preferred). Emphasis should be placed on studies conducted after 1980, when methodological limitations in measuring chromium were resolved.

**Side effects and contraindications.** The toxicity of dietary chromium (Cr+3) is believed to be low in comparison to other trace elements.<sup>2</sup> (Hexavalent chromium [+6], a known human carcinogen, is not present in the food supply in significant quantities.) The Environmental Protection Agency sets toxicity rates at intakes >1 mg/kg body weight/day.<sup>5</sup>

Cell culture studies have suggested that high doses of chromium picolinate may cause increased rates of chromosomal damage.<sup>19</sup> It is not certain whether chromium or picolinate were responsible for these effects, which have not been seen in in vivo human or animal studies.

There are case reports of renal and hepatic toxicity, rhabdomyolysis, psychiatric disturbances, and hypoglycemia with large doses of chromium.<sup>20</sup> In many, chromium has not been unequivocally established as the sole etiological agent.

High doses of chromium have been shown to decrease zinc absorption and may compete with iron for transport on transferrin.<sup>4,19</sup> Vitamin C and aspirin may increase chromium absorption, but in cell culture studies, vitamin C enhanced chromium's genotoxic effects.<sup>19</sup>

**Clinical application.** Accurate biochemical indices of chromium status are not available, so assessment of status and responsiveness to supplementation can only be established by a supplement trial. Positive effects should be seen within 6–12 weeks of supplementation.<sup>5</sup> If clear evidence of benefit is not established, supplementation should be discontinued because chronic use of chromium may increase the risk for as-yet-unidentified toxicities.

Supplements of up to 200 µg are unlikely to be harmful, but the safety of higher doses, which have been shown to be more effective, is less certain. Chromium picolinate and chromium nicotinate appear to have increased bioactivity when compared to inorganic forms of chromium, such as chromium chloride. The ADA does not recommend chromium supplementation for people with diabetes.<sup>21</sup>

The prevalence of chromium defi-

ciency is unknown, but consuming good sources of chromium, such as whole grains, cheese, dried beans, nuts/seeds, mushrooms, beef, wheat germ, and broccoli, will increase the likelihood of meeting nutritional recommendations.<sup>4</sup> Adequate blood glucose control and decreased intake of simple sugars may reduce urinary chromium loss.<sup>4,5</sup>

Because chromium appears to increase the activity of the insulin receptor, it is logical to expect that adequate levels of insulin must also be present. Patients using chromium supplements should be cautioned about the potential for hypoglycemia, and monitoring renal function is prudent.

### Vanadium

The trace element vanadium has not been established as an essential nutrient, and human deficiency has not been documented.<sup>4,22</sup> Vanadium exists in several valence states, with vanadate (+4) and vanadyl (+5) forms most common in biological systems. Vanadyl sulfate and sodium metavanadate are the most common supplemental forms, but other organic vanadium compounds have been developed.

In animal models, vanadium has been shown to facilitate glucose uptake and metabolism, facilitate lipid and amino acid metabolism, improve thyroid function, enhance insulin sensitivity, and negatively affect bone and tooth development in high doses.<sup>23,24</sup> In humans, pharmacological doses alter lipid and glucose metabolism by enhancing glucose oxidation, glycogen synthesis, and hepatic glucose output.<sup>23,24</sup> Vanadium acts primarily as an insulinmimetic agent, although enhanced insulin activity and increased insulin sensitivity have also been noted.<sup>23,24</sup> More recent research suggests that insulin may be required for its effects.<sup>24</sup>

Vanadium is ubiquitous in the environment but is present in extremely small quantities. This makes it difficult to accurately measure status or to induce deficiencies.<sup>4,22</sup> There are no accurate assays for clinical settings.<sup>22</sup> There is also no RDA. The usual U.S. diet is estimated to provide 10–60 µg/day.<sup>22</sup>

Vanadium is stored primarily in bone and transported in the bloodstream on transferrin.<sup>22</sup> It is cleared primarily through the kidney.<sup>22</sup>

**Mechanism of action.** Vanadium's chemical structure is similar to that of

phosphorus, which appears to influence its biochemical actions. It may act as a phosphate analog and has been shown to alter the rate of activity of a number of adenosine triphosphatases, phosphatases, and phosphotransferases.<sup>23</sup>

Vanadium appears to affect several points in the insulin signaling pathway and may lead to upregulation of the insulin receptor and subsequent intracellular signaling pathways.<sup>23,24</sup> Suggested effects include insulin receptor autophosphorylation, increased protein tyrosine and serine threonine kinase activity, inhibition of phosphotyrosine phosphatase activity, increased adenylate cyclase activity, altered glucose-6-phosphatase activity, inhibition of hepatic gluconeogenesis, and increased glycogen synthesis.<sup>23,24</sup>

**Evidence-based research.** Several small trials<sup>25–28</sup> have evaluated the use of oral vanadium supplements in diabetes. Most focused on type 2 diabetes,<sup>25–28</sup> although animal studies suggest that vanadium also has potential benefit in type 1 diabetes.<sup>23</sup>

In subjects with type 2 diabetes, vanadium increased insulin sensitivity as assessed by euglycemic, hyperinsulinemic clamp studies in some,<sup>25–27</sup> but not all,<sup>28</sup> trials. Glucose oxidation and glycogen synthesis were increased, and hepatic glucose output was suppressed in two studies.<sup>26,27</sup>

In type 1 diabetes, vanadium did not affect insulin sensitivity, although daily insulin doses declined.<sup>25</sup> Supplementation decreased FBG,<sup>26–28</sup> HbA<sub>1c</sub>,<sup>26,27</sup> and cholesterol levels<sup>25</sup> and stimulated kinase activity.<sup>25</sup>

Pharmacological doses appear to have a mild effect on insulin sensitivity and glucose utilization in type 2 diabetes. Effects in animal models are stronger than in humans, and there is no information on the long-term effects in diabetes.

Research on vanadium is summarized in Table 2. When evaluating these studies, one should pay particular attention to the form of vanadium utilized, specific animal model of diabetes used or type of diabetes in humans, doses, physiological relevance of the results, length of study, and the impact on food intake and weight caused by the anorexiatic effects of vanadium. It is also important to look at study design, controls, washout period, and assay methods, especially in vitro phosphorylation assays, which are notoriously difficult to conduct well.

Table 2. Select Vanadium Clinical Trials

Ref.	Subjects	Design	Results	Notes
25	<ul style="list-style-type: none"> <li>• 5 type 1</li> <li>• 5 type 2</li> <li>• Age 28–65 years</li> <li>• BMI 21.7–30.8</li> <li>• HbA<sub>1c</sub> 7.7–19.5%</li> <li>• I, O</li> </ul>	<ul style="list-style-type: none"> <li>• Non-randomized, non-placebo-controlled</li> <li>• 2 weeks</li> <li>• 125 mg/day sodium metavanadate</li> </ul>	<ul style="list-style-type: none"> <li>• Vd increased glucose disposal (29%, <math>P &lt; 0.05</math>) in the first phase of two-step euglycemic hyperinsulinemic clamp in subjects with type 2</li> <li>• No change in insulin sensitivity in type 1, but insulin doses did decrease (<math>P &lt; 0.05</math>)</li> <li>• No change in HbA<sub>1c</sub>, fructosamine, basal HGO, HGO suppression</li> <li>• Total cholesterol decreased in type 2 (<math>P &lt; 0.05</math>)</li> <li>• MAP and S6 kinase activity increased in both groups</li> </ul>	<ul style="list-style-type: none"> <li>• Divided dose taken 3 times/day</li> <li>• No change in weight or calorie intake for duration of study</li> <li>• No biochemical evidence of toxicity</li> <li>• Side effects primarily GI: nausea, vomiting, mild diarrhea, hypoglycemia</li> </ul>
28	<ul style="list-style-type: none"> <li>• 8 type 2</li> <li>• BMI 31.5</li> <li>• Age 53.5 years</li> <li>• I, O</li> </ul>	<ul style="list-style-type: none"> <li>• Single-blind, placebo-controlled</li> <li>• 100 mg/day vanadyl sulfate</li> <li>• 4 weeks</li> </ul>	<ul style="list-style-type: none"> <li>• Vd decreased FBG by 20% (<math>P &lt; 0.05</math>), decreased HGO (<math>P &lt; 0.02</math>) and had no effect on glucose uptake, oxidation, or glycogen synthesis</li> <li>• Decrease in HGO maintained in placebo phase</li> </ul>	<ul style="list-style-type: none"> <li>• Placebo followed active treatment and 2- to 4-week washout period.</li> <li>• Side effects primarily GI discomfort, mild diarrhea; transient in nature</li> <li>• Baseline HbA<sub>1c</sub> not provided</li> </ul>
27	<ul style="list-style-type: none"> <li>• 6 type 2</li> <li>• Age 50 years</li> <li>• BMI 27.3</li> <li>• D, O</li> <li>• HbA<sub>1c</sub> 9.6%</li> </ul>	<ul style="list-style-type: none"> <li>• Single-blind, placebo-controlled</li> <li>• 100 mg/day vanadyl sulfate</li> <li>• 3 weeks</li> </ul>	<ul style="list-style-type: none"> <li>• Vd decreased FPG from 210 to 181 mg/dl (<math>P &lt; 0.05</math>)</li> <li>• HbA<sub>1c</sub> decreased from 9.6 to 8.8% (<math>P &lt; 0.05</math>)</li> <li>• Euglycemic hyperinsulinemic clamp indicated increased glucose uptake and disposal (<math>P &lt; 0.0001</math>), inhibition of HGO (<math>P &lt; 0.0001</math>), increased CHO oxidation (<math>P &lt; 0.05</math>) from increased glycogen synthesis (<math>P &lt; 0.003</math>), and decreased FFA levels (<math>P &lt; 0.0001</math>)</li> <li>• No change in fructosamine levels, OGTT response, or insulin levels</li> </ul>	<ul style="list-style-type: none"> <li>• Divided placebo 2 weeks before and 2 weeks after treatment</li> <li>• BMI wide range 23–38</li> <li>• Hb and Hct decreased in Vd subjects</li> <li>• 1% decrease in body weight</li> </ul>
26	<ul style="list-style-type: none"> <li>• 6 type 2</li> <li>• 6 control</li> <li>• Age 53 years</li> <li>• BMI 28.7</li> <li>• HbA<sub>1c</sub> 9.4%</li> <li>• D, O</li> </ul>	<ul style="list-style-type: none"> <li>• Single-blind, placebo-controlled</li> <li>• 100 mg/day vanadyl sulfate</li> </ul>	<ul style="list-style-type: none"> <li>• In subjects with type 2, Vd decreased FPG (<math>P &lt; 0.01</math>) and HbA<sub>1c</sub> (9.4 to 8.8%) (<math>P &lt; 0.01</math>)</li> <li>• In type 2, euglycemic hyperinsulinemic clamp increased glucose utilization (<math>P &lt; 0.05</math>) (associated with increased glycogen synthesis <math>P &lt; 0.005</math>) and CHO oxidation (<math>P &lt; 0.05</math>) and decreased HGO (<math>P &lt; 0.005</math>)</li> <li>• In type 2, Vd decreased total cholesterol (<math>P &lt; 0.05</math>) and FFA (<math>P &lt; 0.010</math>)</li> </ul>	<ul style="list-style-type: none"> <li>• Data for 5 of the 7 diabetic subjects previously reported in ref. 27</li> <li>• Control BMI 29.5</li> <li>• No change in weight</li> <li>• Only small change in cholesterol</li> <li>• Minor GI side effects</li> </ul>

CHO, cholesterol; D, use of medical nutrition or diet therapy; FBG, fasting blood glucose; FFA, free fatty acid; FPG, fasting plasma glucose; GI, gastrointestinal; Hct, hematocrit; HGO, hepatic glucose output; I, use of insulin; MAP, mitogen-activated protein; O, use of oral diabetes medication; OGTT, oral glucose tolerance test; Vd, vanadium.

### Side effects and contraindications.

Because it is needed in such small quantities (in animals 50–500 ppb supports growth) and body stores are so low (100  $\mu$ g), relatively small doses of supplemental vanadium are potentially toxic.<sup>22</sup> Patients using oral supplements most commonly report nausea, vomiting, cramping, flatulence, and diarrhea.<sup>25–28</sup> These effects are transient and improve with a decrease in dose.

Longer-term use has been associated with anorexia, decreased food and fluid intake, and weight loss. Animal studies indicate that long-term, high-dose supplementation (>10 mg/day of elemental vanadium) can be toxic, with neurological, hematological, nephrotoxic, hepatotoxic, and reproductive and developmental effects.<sup>4,22</sup>

Vanadium may enhance the activity of digoxin and anticoagulant medications.<sup>20</sup> Excessive intakes may result in a green discoloration of the tongue.<sup>4</sup> Limiting daily intake to <100  $\mu$ g/day has been recommended.<sup>22</sup>

**Clinical application.** There is insufficient information on the long-term effects of pharmacological doses of vanadium to recommend its use in diabetes. Chronic intake of relatively small doses could have significant adverse effects.

Researchers are working to develop forms of vanadium that are better absorbed and have fewer side effects. Good dietary sources include black pepper, dill, parsley, mushrooms, spinach, oysters, shellfish, cereals, fish, and wine.<sup>4</sup>

### Nicotinamide

Niacin (vitamin B<sub>3</sub>) occurs in two forms: nicotinic acid and nicotinamide. The active coenzyme forms (nicotinamide adenine dinucleotide [NAD] and NAD phosphate) are essential for the function of hundreds of enzymes and normal carbohydrate, lipid, and protein metabolism.<sup>2,4</sup>

As a vitamin, the two compounds function similarly, but in pharmacological doses they have distinct effects. Nicotinic acid (1–3 g/day) is an effective treatment for dyslipidemia,<sup>4</sup> although its use in people with diabetes has been limited because of its negative effect on glycemic control. Pharmacological doses of nicotinamide are being studied for their potential benefit in the prevention<sup>29–32</sup> and treatment<sup>33–37</sup> of diabetes.

The DRIs for niacin are reported in niacin equivalents (NE) because niacin can be synthesized by the body from tryptophan. The RDA is 14 mg NE for women and 16 mg NE for men. The UL is 35 mg NE/day for adults. Niacin deficiency (pellagra) is not common in the United States.

**Mechanism of action.** Animal studies suggest that nicotinamide acts by protecting pancreatic  $\beta$ -cells from autoimmune destruction by maintaining intracellular NAD levels and inhibiting the enzyme poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA repair. Excessive PARP induction results in depletion of cytoplasmic NAD levels, induction of immunoregulatory genes, and cellular apoptosis (programmed cell death). Nicotinamide may additionally act as a weak antioxidant of nitric oxide radicals.<sup>38,39</sup>

**Evidence-based research.** The effects of nicotinamide supplementation have been studied in several trials focusing on the development<sup>29-32</sup> and progression<sup>34-36</sup> of type 1 diabetes; a meta-analysis;<sup>33</sup> and one small trial in type 2 diabetes.<sup>37</sup> Results have been mixed, and the largest clinical trial, the European Nicotinamide Diabetes Intervention Trial (ENDIT), is not yet complete.<sup>32</sup>

Nicotinamide appears to be most effective in newly diagnosed diabetes and in subjects with positive islet cell antibodies but not diabetes. People who develop type 1 diabetes after puberty appear to be more responsive to nicotinamide treatment.<sup>33-36</sup> Study results have offered more support for the idea that nicotinamide helps to preserve  $\beta$ -cell function<sup>33</sup> than for its possible role in diabetes prevention.<sup>30</sup>

Research on nicotinamide is summarized in Table 3. When evaluating these studies, one should pay particular attention to subjects' age of diabetes onset, duration of diabetes, and form of diabetes; the dose and form of nicotinamide used; the clinical significance of effects; and effects on growth in pediatric populations.

**Side effects and contraindications.** Nicotinamide is a water-soluble vitamin and thus is not stored in the body.<sup>2</sup> It is relatively safe with few significant side effects.<sup>39</sup> Adverse effects have included skin reactions (flushing), abnormal prothrombin times, hepatotoxicity, nausea, vomiting, diarrhea, headache, dizziness, blurry vision, heartburn, sore mouth, and fatigue.<sup>1,4,20</sup>

Nicotinamide interacts with some anticonvulsants by increasing serum concentrations.<sup>20</sup> Its use is contraindicated in active liver disease and may worsen gallbladder disease, gout, peptic ulcer disease, and allergies.<sup>20</sup> In animal models, high doses have caused growth retardation, but this has not been seen in human studies.<sup>39</sup> One trial noted decreases in first-phase insulin release<sup>30</sup> with nicotinamide supplementation, and a second trial noted decreased insulin sensitivity.<sup>29</sup>

**Clinical application.** Nicotinamide may help to preserve residual  $\beta$ -cell function in people with type 1 or type 2 diabetes, but it does not lead to clinically significant improvements in metabolic control. Typical doses are 25-50 mg/kg/day. Of concern are potential negative effects on insulin release, insulin sensitivity, and growth.

Any role that nicotinamide may have in prevention of type 1 diabetes should be elucidated at the conclusion of the ENDIT study sometime after 2003.<sup>39</sup> Until then, the efficacy and safety of long-term, high-dose nicotinamide supplementation are unclear. Monitoring liver enzymes and platelet function is prudent if using high-dose nicotinamide supplements. Good dietary sources of niacin include fortified grains, some cereals, meats, fish, and dried beans.<sup>4</sup>

## Magnesium

The mineral magnesium functions as an essential cofactor for more than 300 enzymes. It is essential for all energy-dependent transport systems, glycolysis, oxidative energy metabolism, biosynthetic reactions, normal bone metabolism, neuromuscular activity, electrolyte balance, and cell membrane stabilization.<sup>40</sup> The kidney primarily regulates magnesium homeostasis.

Magnesium deficiency has been associated with hypertension, insulin resistance, glucose intolerance, dyslipidemia, increased platelet aggregation, cardiovascular disease, complications of diabetes, and complications of pregnancy.<sup>2,3,40,41</sup> Whether poor magnesium status plays a causal role in these disorders or is simply associated with them has not been determined.

Less than 0.3% of the body's magnesium pool is found in serum, and extracellular magnesium levels do not reflect functionally important body pools. This makes assessment of magnesium status difficult.<sup>2,40,41</sup> Serum

magnesium is a specific, but not sensitive, indicator of magnesium deficiency; low serum magnesium levels indicate low magnesium stores, but a deficiency must be severe before serum levels decline. More sensitive assays are being developed.<sup>2,40,41</sup>

Magnesium is one of the more common micronutrient deficiencies in diabetes.<sup>2,3,40,41</sup> Decreased magnesium levels and increased urinary magnesium losses have been documented in both type 1 and type 2 diabetic patients.<sup>2,40-45</sup> Low dietary magnesium intake has been associated with increased incidence of type 2 diabetes in some,<sup>46</sup> but not all,<sup>47</sup> studies.

Hypomagnesemia in diabetes is most likely due to increased urinary losses.<sup>40,41</sup> Additional risk factors include ketoacidosis, use of certain medications including digitalis and diuretics, malabsorption syndromes, congestive heart failure, myocardial infarction (MI), electrolyte disturbances, acute critical illness, alcohol abuse, and pregnancy.<sup>40,41</sup> Low-calorie and poor-quality diets are more likely to be inadequate in magnesium. People with diabetes may have diets low in magnesium.<sup>48</sup> Hypermagnesemia may occur with renal insufficiency that impairs magnesium clearance.<sup>40,41</sup>

The RDA is 400 mg/day for men under age 30, 420 mg/day for men over age 30, 310 mg/day for women under 30, and 320 mg/day for women over age 30. The UL is 350 mg/day as supplemental magnesium. Daily intake from food and water is not included in the UL.

**Mechanism of action.** The mechanisms by which magnesium affects insulin resistance, hypertension, and cardiovascular disease are unknown. However, the widespread use of magnesium in normal metabolism of macronutrients, cellular transport systems, intracellular signaling systems, platelet aggregation, vascular smooth muscle tone and contractility, electrolyte homeostasis, and phosphorylation and dephosphorylation reactions<sup>1</sup> suggests that these effects are multifactorial.

**Evidence-based research.** Research has focused on the following areas:

- **Glycemic control.** An inverse relationship between plasma magnesium levels and indices of glycemic control has been noted in both type 1 and type 2 diabetes.<sup>42,43</sup> Clinical studies evaluating the effect of supplemental magnesium on glycemic control

Table 3. Select Nicotinamide Clinical Trials

Ref.	Subjects	Design	Results	Notes
31	<ul style="list-style-type: none"> <li>• 173 positive ICA</li> <li>• Age 5–8 years</li> <li>• New Zealand</li> </ul>	<ul style="list-style-type: none"> <li>• Not placebo-controlled</li> <li>• 1,000 mg/day Nic</li> <li>• Mean follow-up 7 years</li> </ul>	<ul style="list-style-type: none"> <li>• Nic associated with significant decreases in the development of type 1 diabetes (<math>P &lt; 0.008</math>), wide confidence interval</li> </ul>	<ul style="list-style-type: none"> <li>• Clinically significant decrease in incidence of diabetes: 41% of that in non-treated group</li> </ul>
30	<ul style="list-style-type: none"> <li>• 55 positive ICA</li> <li>• Siblings of type 1</li> <li>• Age 3–12 years</li> <li>• Germany</li> </ul>	<ul style="list-style-type: none"> <li>• RDBPCT; DENIS trial</li> <li>• 1.2 g/m<sup>2</sup> body surface/day</li> <li>• Slow-release Nic</li> <li>• Follow-up 2–3 years</li> </ul>	<ul style="list-style-type: none"> <li>• Rates of diabetes were similar in the Nic and placebo groups</li> <li>• Nic decreased first-phase insulin response (40%) to glucose (<math>P &lt; 0.03</math>)</li> </ul>	<ul style="list-style-type: none"> <li>• Trial ended early due to lack of effect of Nic (<math>P &lt; 0.97</math>)</li> <li>• Very-high-risk group of subjects</li> </ul>
29	<ul style="list-style-type: none"> <li>• 8 positive ICA</li> <li>• Siblings of type 1</li> <li>• Mean age 39 years</li> </ul>	<ul style="list-style-type: none"> <li>• Not randomized</li> <li>• No placebo</li> <li>• 2 g/day slow-release Nic</li> <li>• 2 weeks</li> </ul>	<ul style="list-style-type: none"> <li>• Nic decreased insulin sensitivity 23.6% (<math>P &lt; 0.02</math>)</li> <li>• Insulin sensitivity improved in most subjects after discontinued Nic</li> <li>• No clear effect on acute insulin response; increased in some subjects</li> </ul>	<ul style="list-style-type: none"> <li>• Subjects tested at baseline, after 2 weeks Nic, and 2 weeks after treatment</li> <li>• Doses ranged from 19.1 to 40.5 mg/kg</li> </ul>
32	<ul style="list-style-type: none"> <li>• Goal 422 positive ICA</li> <li>• First-degree relative type 1</li> <li>• Age 5–40 years</li> </ul>	<ul style="list-style-type: none"> <li>• Randomized, placebo-controlled</li> <li>• Multicenter/multi-country</li> <li>• Goal follow-up 5 years</li> <li>• 1,200 mg/M<sup>2</sup>/day</li> <li>• Slow-release Nic</li> </ul>	<ul style="list-style-type: none"> <li>• Treatment started in 1994; results expected after 2002</li> </ul>	
33	<ul style="list-style-type: none"> <li>• 211 type 1</li> <li>• Recent diagnosis</li> <li>• Ages 4–48 years</li> </ul>	<ul style="list-style-type: none"> <li>• Meta-analysis</li> <li>• 10 randomized studies, 5 placebo-controlled</li> <li>• Dose 4–100 mg/kg/day</li> <li>• Up to 60 months follow-up</li> </ul>	<ul style="list-style-type: none"> <li>• 1 year after diagnosis, baseline C-peptide levels significantly higher in Nic group (<math>P &lt; 0.005</math>), placebo-controlled group (<math>P &lt; 0.05</math>)</li> <li>• No differences in HbA<sub>1c</sub> or insulin requirements</li> </ul>	
34	<ul style="list-style-type: none"> <li>• 36 type 1</li> <li>• Mean age 18 years</li> <li>• Recent diagnosis</li> </ul>	<ul style="list-style-type: none"> <li>• Open controlled trial</li> <li>• 200 mg/day Nic</li> <li>• 4 weeks</li> </ul>	<ul style="list-style-type: none"> <li>• Stimulated C-peptide levels significantly higher at 6 months (<math>P &lt; 0.04</math>) and 1 year (<math>P &lt; 0.01</math>) compared to diagnosis</li> <li>• Decreased HbA<sub>1c</sub> in Nic (<math>P &lt; 0.03</math>) at 1 year compared to control</li> </ul>	<ul style="list-style-type: none"> <li>• No difference in remission rate</li> <li>• No serious side effects</li> <li>• Lower insulin doses in Nic group</li> </ul>
35	<ul style="list-style-type: none"> <li>• 56 type 1</li> <li>• Recent diagnosis</li> <li>• Mean age 18 years</li> <li>• HbA<sub>1c</sub> 8.7%</li> </ul>	<ul style="list-style-type: none"> <li>• DBPCT</li> <li>• 25 mg/kg/day</li> <li>• 1 year</li> </ul>	<ul style="list-style-type: none"> <li>• Stimulated C-peptide levels were increased in the group of Nic-treated patients &gt;15 years old (<math>P &lt; 0.02</math>)</li> <li>• No other differences between Nic and placebo were seen.</li> </ul>	
36	<ul style="list-style-type: none"> <li>• 74 type 1</li> <li>• Recent diagnosis</li> </ul>	<ul style="list-style-type: none"> <li>• Randomized, non-placebo</li> <li>• 25 mg/kg/day, 50 mg/kg/day</li> <li>• 1 year</li> </ul>	<ul style="list-style-type: none"> <li>• No significant differences between the 2 groups at 1 year</li> <li>• Trend toward higher insulin doses in the 50 mg/kg/day group</li> </ul>	
37	<ul style="list-style-type: none"> <li>• 18 type 2</li> <li>• Negative ICA</li> <li>• OHA failure</li> <li>• BMI &lt;25</li> </ul>	<ul style="list-style-type: none"> <li>• Randomized, single-blind, placebo</li> <li>• 6 months</li> <li>• 1.5 g/day Nic</li> <li>• I plus Nic, I plus placebo, OHA plus Nic</li> </ul>	<ul style="list-style-type: none"> <li>• C-peptide release increased in two groups receiving Nic compared to placebo (<math>P &lt; 0.05</math>)</li> <li>• No difference in HbA<sub>1c</sub>, FBG, or mean daily BG between groups</li> </ul>	

BG, blood glucose; FBG, fasting blood glucose; DBPCT, double blind placebo controlled trial; I, use of insulin; DENIS, Deutsch Nicotinamide Intervention Study; ICA, islet cell antibodies; Nic, nicotinamide; OHA, oral hypoglycemic agent; RDBPCT, randomized, double-blind, placebo-controlled trial.

are mixed, with some studies reporting improvements<sup>44,49</sup> and others showing no improvement.<sup>45,50,51</sup>

- **Insulin sensitivity.** Diets low in magnesium are associated with

increased insulin levels,<sup>52</sup> and clinical magnesium deficiency is strongly associated with insulin resistance.<sup>40,41</sup> It is not known if low magnesium levels play a role in the development of insulin

resistance, are a result of insulin resistance, or are simply a coexisting condition. In vitro evidence suggests that insulin plays a role in magnesium transport, and insulin resistance has been

shown to decrease magnesium uptake in type 2 diabetes.<sup>40</sup> Conversely, magnesium supplementation has a mild positive effect on insulin sensitivity.<sup>40,49,53</sup> Animal models show decreased insulin receptor tyrosine kinase activity and decreased glucose uptake and oxidation in magnesium deficiency.<sup>40</sup> Supplementation trials have primarily focused on type 2 diabetes.

- **Hypertension.** Observational studies indicate an inverse relationship between magnesium levels and hypertension in people with and without diabetes. Clinical trials have produced inconsistent results.<sup>54</sup>
- **Cardiovascular disease.** Magnesium deficiency is associated with dyslipidemias, atherosclerosis, acute MI, and cardiovascular disease (CVD)<sup>41,55</sup> and has been shown to alter platelet aggregation and activity.<sup>3,40,41,55</sup> Most trials in type 2 diabetes have shown little effect of supplementation on lipid levels,<sup>45,50,51</sup> although improvement in the magnesium status of subjects with type 1 diabetes was associated with mild improvements in triglycerides.<sup>55</sup>
- **Complications.** Some,<sup>47</sup> but not all,<sup>56</sup> research suggests that subjects with common microvascular complications of diabetes have lower serum magnesium levels than subjects without complications. Patients with retinopathy have been found to have lower magnesium levels than control subjects or diabetic subjects without retinopathy.<sup>40</sup> Intracellular magnesium levels were lower in patients with neuropathy.<sup>44</sup> In type 2 diabetic subjects, micro- and macroalbuminuria were associated with lower serum ionized magnesium levels than was normoalbuminuria.<sup>57</sup>

Research on magnesium is summarized in Table 4. When evaluating these studies, one should pay particular attention to the characteristics of the population studied; the etiology of diabetes; the presence of obesity; subjects' age, renal function, diet composition, oral hypoglycemic or insulin use, and degree of glycemic control; the dose and form of magnesium, subjects' baseline magnesium status and

response to supplementation; assessment methods; length of trial; and the study design and ability to identify causality.

**Side effects and contraindications.** Magnesium is relatively nontoxic in people with normal renal function. Chronic supplementation and use of magnesium-containing medications such as laxatives and antacids can lead to hypermagnesemia in people with impaired renal function, defined as creatinine clearance <30 ml/min.<sup>40</sup> Hypermagnesemia can result in hypotension, headaches, nausea, altered cardiac function, central nervous system disorders, and death.<sup>1,4</sup>

**Clinical application.** The ADA recommends assessment of magnesium status in patients at risk for deficiency and supplementation for documented deficiencies.<sup>41</sup>

Oral supplements are available in numerous forms, but some research suggests that magnesium citrate is more bioavailable.<sup>4</sup> Supplements up to the UL of 350 mg/day are appropriate; intakes >500 mg/day of elemental magnesium may cause diarrhea.<sup>4</sup>

Effects of supplementation on indices of magnesium status are mixed,<sup>40,41</sup> but some research suggests that relatively high doses of magnesium for 1–3 months followed by lower daily supplements are needed to restore and maintain magnesium in people with diabetes.<sup>44,45</sup>

In patients with renal insufficiency, supplementation must be monitored closely. Adequate dietary intakes and good glycemic control should be encouraged to prevent deficiency. Good dietary sources include whole grains, leafy green vegetables, legumes, nuts, and fish.<sup>4</sup> Diets high in saturated fat, fructose, caffeine, and alcohol may increase magnesium needs.<sup>1,4,40</sup>

### Vitamin E

This essential fat-soluble vitamin functions primarily as an antioxidant.<sup>1</sup> Free radical damage is believed to play a role in many diseases, such as CVD and cancer, as well as in normal cellular aging. Antioxidants have been proposed as preventive and treatment agents for these conditions.<sup>4</sup>

Low levels of vitamin E are associated with increased incidence of diabetes,<sup>58</sup> and some research suggests that people with diabetes have decreased levels of antioxidants.<sup>59</sup> People with diabetes may also have greater antioxidant requirements

because of increased free radical production with hyperglycemia.<sup>60,61</sup>

Increased levels of oxidative stress markers have been documented in people with diabetes.<sup>62,63</sup> Improvement in glycemic control decreases markers of oxidative stress,<sup>60</sup> as does vitamin E supplementation.<sup>60,64,65</sup>

Clinical trials involving people with diabetes have investigated the effect of vitamin E on diabetes prevention,<sup>66</sup> insulin sensitivity,<sup>67,68</sup> glycemic control,<sup>69–71</sup> protein glycation,<sup>72</sup> microvascular complications of diabetes,<sup>73,74</sup> and cardiovascular disease and its risk factors.<sup>64,65,75,76</sup>

Vitamin E refers to a group of compounds that includes tocopherols and tocotrienols. Alpha-tocopherol is the most abundant and biologically active.<sup>4</sup> Usual dietary intakes are estimated at 7–11 mg/day.<sup>4</sup> The RDA for alpha-tocopherol is 15 mg/day for people 15 years of age and older. The UL for alpha-tocopherol is 1,000 mg/day from supplemental sources. Natural vitamin E (d-alpha tocopherol) has approximately twice the bioactivity of synthetic forms of the vitamin (dl-alpha tocopherol).<sup>4</sup>

**Mechanism of action.** Vitamin E is a potent lipophilic antioxidant. It acts to neutralize free radical species produced during normal cellular metabolism, protecting cellular membranes and lipoproteins—LDL in particular—from oxidative damage. It also interacts with water-soluble antioxidants such as glutathione.<sup>1,4</sup> It may play a role in preventing and treating common complications of diabetes, such as CVD, nephropathy, and neuropathy, by decreasing protein glycation, lipid oxidation, and inhibition of platelet adhesion and aggregation.<sup>64,65,72–74,76</sup>

**Evidence-based research.** Studies have focused on the following areas:

- **CVD.** People with diabetes are at increased risk for CVD.<sup>64,65</sup> Dietary vitamin E has been associated with decreased incidence of CVD,<sup>77,78</sup> and in subjects without diabetes, supplementation has improved cardiovascular outcomes in some,<sup>79</sup> but not all, studies. A large recent intervention trial including 3,577 people with diabetes found no beneficial effect on cardiovascular outcomes with 400 IU of natural vitamin E/day for 4.5 years.<sup>75</sup>

The effects of supplementation on CVD risk factors in diabetes are mixed.<sup>96</sup> Positive effects



Table 4. Select Magnesium Clinical Trials

Ref.	Subjects	Design	Results	Notes
51	<ul style="list-style-type: none"> <li>• 50 type 2</li> <li>• Netherlands</li> <li>• I</li> <li>• BMI 28</li> <li>• HbA<sub>1c</sub> 8.7%</li> </ul>	<ul style="list-style-type: none"> <li>• RDBPCT</li> <li>• 15 mmol/day</li> <li>• Oral MgAspHCl</li> <li>• 3 months</li> <li>• Intention to treat and on-treatment</li> </ul>	<ul style="list-style-type: none"> <li>• Mg supplementation slightly increased plasma Mg levels (<math>P &lt; 0.05</math>); no change in RBC Mg, which was not low</li> <li>• No change in FBG, HbA<sub>1c</sub></li> <li>• No change in lipids or hypertension</li> </ul>	<ul style="list-style-type: none"> <li>• Increased plasma Mg irrespective of group was associated with a decrease in diastolic BP</li> <li>• No side effects noted</li> <li>• 16 drop-outs</li> </ul>
44	<ul style="list-style-type: none"> <li>• 128 type 2</li> <li>• BMI 25</li> <li>• D, O, M</li> <li>• Brazil</li> <li>• HbA<sub>1c</sub> &gt;8%</li> </ul>	<ul style="list-style-type: none"> <li>• RDBPCT</li> <li>• Oral Mg oxide</li> <li>• 20.7 mmol/day; 41.4 mmol/day, placebo</li> <li>• 30 days</li> <li>• Intention to treat</li> </ul>	<ul style="list-style-type: none"> <li>• Subjects with diabetes had decreased intramononuclear Mg (<math>P &lt; 0.05</math>) but not plasma Mg</li> <li>• No correlation between intramononuclear Mg and glycemic control</li> <li>• 41.4 mmol Mg increased plasma Mg and decreased fructosamine levels (<math>P &lt; 0.05</math>)</li> <li>• Subjects with peripheral neuropathy (<math>P &lt; 0.05</math>) and CVD (<math>P &lt; 0.05</math>) had lower intramononuclear Mg levels than those with diabetes but no complications or retinopathy</li> </ul>	<ul style="list-style-type: none"> <li>• GI side effects: diarrhea, abdominal pain, nausea</li> <li>• No correlation between plasma and intracellular Mg</li> <li>• 29 subjects did not follow protocol</li> <li>• No change in weight</li> </ul>
45	<ul style="list-style-type: none"> <li>• 40 type 2</li> <li>• HbA<sub>1c</sub> 7.4%</li> <li>• BMI 28</li> <li>• Austria</li> <li>• D plus O, M</li> </ul>	<ul style="list-style-type: none"> <li>• RDBPCT</li> <li>• Oral Mg</li> <li>• 30 mmol/day</li> <li>• 3 months</li> </ul>	<ul style="list-style-type: none"> <li>• Plasma Mg in diabetes significantly lower than in healthy controls (<math>P &lt; 0.0001</math>)</li> <li>• Mg increased plasma Mg to levels similar to control group at 3 months</li> <li>• No change in HbA<sub>1c</sub>: 7.4% pre-Mg, 7.2% post-Mg; no change in basal or OGTT insulin levels or BG levels</li> <li>• No change in lipid levels</li> </ul>	<ul style="list-style-type: none"> <li>• 6 month follow-up found Mg levels declined to pre-Mg levels</li> <li>• 2 months of treatment did not increase plasma Mg</li> <li>• Diet questionnaire to assess Mg intake</li> </ul>
53	<ul style="list-style-type: none"> <li>• 9 type 2</li> <li>• BMI 25.8</li> <li>• Mean age 73 years</li> <li>• D</li> <li>• HbA<sub>1c</sub> ?</li> <li>• Italy</li> </ul>	<ul style="list-style-type: none"> <li>• RDBPCT crossover</li> <li>• 4-week treatment</li> <li>• 4-week washout</li> <li>• 15.8 mmol/day</li> <li>• Oral Mg pidolate</li> </ul>	<ul style="list-style-type: none"> <li>• Mg increased plasma and RBC Mg (both <math>P &lt; 0.001</math>)</li> <li>• FBG did not change</li> <li>• Euglycemic hyperinsulinemic clamp increased insulin-mediated glucose disposal (<math>P &lt; 0.005</math>), total body glucose disposal (<math>P &lt; 0.005</math>), and glucose oxidation (<math>P &lt; 0.01</math>)</li> </ul>	
50	<ul style="list-style-type: none"> <li>• 56 type 2</li> <li>• Age 64±8 years</li> <li>• D, O, I</li> <li>• BMI~25</li> <li>• HbA<sub>1c</sub> 7.3%</li> </ul>	<ul style="list-style-type: none"> <li>• RDBPCT</li> <li>• 15 mmol/day</li> <li>• Mg lactate citrate</li> <li>• 4 months</li> </ul>	<ul style="list-style-type: none"> <li>• No effect of Mg on HbA<sub>1c</sub>, FBG, lipids, renal function, or blood pressure</li> </ul>	<ul style="list-style-type: none"> <li>• All subjects had normal plasma Mg initially</li> </ul>
49	<ul style="list-style-type: none"> <li>• 8 type 2</li> <li>• Age 72 years</li> <li>• 133% IBW</li> <li>• Italy</li> <li>• HbA<sub>1c</sub> ?</li> </ul>	<ul style="list-style-type: none"> <li>• RPCT crossover</li> <li>• 4-week treatment</li> <li>• 2-week washout</li> <li>• 2 g/day</li> <li>• Oral Mg</li> </ul>	<ul style="list-style-type: none"> <li>• Mg increased plasma (<math>P &lt; 0.05</math>) and RBC Mg (<math>P &lt; 0.01</math>) levels</li> <li>• Mg decreased FBG (<math>P &lt; 0.05</math>)</li> <li>• Euglycemic hyperinsulinemic clamp: Mg increased acute insulin response to glucose pulse (<math>P &lt; 0.05</math>), glucose infusion rate (<math>P &lt; 0.025</math>)</li> </ul>	<ul style="list-style-type: none"> <li>• Oral medications discontinued 3 weeks before study</li> <li>• Diet Mg estimated at 317 mg/day</li> </ul>

BG, blood glucose; BP, blood pressure; D, use of medical nutrition or diet therapy; FBG, fasting blood glucose; GI, gastrointestinal; I, use of insulin; IBW, ideal body weight; M, metformin; Mg, magnesium; MgAspHCl, magnesium aspartate hydrochloride; O, use of oral diabetes medication; OGTT, oral glucose tolerance test; RBC, red blood cell; RDBPCT, randomized, double-blind, placebo-controlled trial; RPCT, randomized, placebo-controlled trial.

on lipid levels or lipid oxidation have been noted in some,<sup>64,70,71</sup> but not other,<sup>69</sup> studies. Improvements have been noted in cell adhesion,<sup>65</sup> platelet aggregation,<sup>65</sup> monocyte proatherogenic activity,<sup>65</sup> and endothelial function.<sup>76</sup> Vitamin E has improved LDL oxidation, but positive effects may be greater for buoyant LDL than for the highly atherogenic dense LDL.<sup>64</sup>

• **Microvascular complications.**

Limited research suggests that vitamin E may be beneficial in preventing or treating microvascular complications of diabetes.<sup>73,74</sup>

- **Insulin resistance and glycemic control.** Some studies have documented improvements in glycemic control<sup>67,70-72</sup> and insulin resistance<sup>67</sup> with vitamin E supplementation, whereas others have noted no effect<sup>64,69</sup> or negative effects.<sup>68</sup>

Research on vitamin E is summarized in Table 5. When evaluating these studies, one should pay particular attention to the population studied, presence of preexisting CVD, type of diabetes, form and dose of vitamin E, duration of supplementation, level of glycemic control, use of a pre-study run-in period, levels of antioxidant body pools, degree of incorporation into lipoproteins, degree of protection from oxidation conferred, assay

method for oxidative markers, effects on mortality, presence of smoking or alcohol use, and supplement use and usual diets of subjects.

**Side effects and contraindications.** Vitamin E is relatively nontoxic.<sup>5</sup> Most long-term trials have found no negative side effects with supplement-

tation.<sup>4,79, 80</sup>

Vitamin E has been shown to have anticoagulant properties, and patients using medications and herbal supplements known to decrease blood clotting, such as warfarin, aspirin, ginkgo biloba, garlic, and ginseng, may be at increased risk for bleeding with high-

dose supplements.<sup>20</sup> Doses of vitamin E up to 400 IU are believed to be safe.<sup>1</sup> Doses >800 IU may alter blood clotting, although trials that have monitored prothrombin times have noted no increases.<sup>4</sup>

Vitamin E has been associated with increased risk of hemorrhagic stroke

**Table 5. Select Vitamin E Clinical Trials**

Ref.	Subjects	Design	Results	Notes
66	<ul style="list-style-type: none"> <li>84 type 1</li> <li>Age 5–35 years</li> <li>HbA<sub>1c</sub> 8.9%</li> </ul>	<ul style="list-style-type: none"> <li>IMDIAB IV study</li> <li>Prospective trial</li> <li>Nonrandomized, non-placebo</li> <li>15 mg/kg/day VE</li> <li>1 year</li> </ul>	<ul style="list-style-type: none"> <li>Conclusion: effects of VE and nicotinamide on <math>\beta</math>-cell preservation similar</li> <li>HbA<sub>1c</sub> and insulin use decreased (<math>P &lt; 0.005</math>).</li> <li>Authors noted similar results with nonsupplement patients in past</li> <li>Basal and stimulated C-peptide levels remained stable over year</li> </ul>	<ul style="list-style-type: none"> <li>Patients &lt;15 years of age had lower C-peptide than patients &gt;15 years of age</li> <li>VE in 1 patient resulted in transient leucopenia</li> <li>Form of VE not specified</li> </ul>
69	<ul style="list-style-type: none"> <li>53 type 2</li> <li>Mexico</li> <li>Age 40 years</li> <li>BMI 24</li> <li>HbA<sub>1c</sub> 11.9%</li> </ul>	<ul style="list-style-type: none"> <li>RDBPCT, crossover</li> <li>400 mg VE</li> <li>2 months</li> <li>4-week washout</li> </ul>	<ul style="list-style-type: none"> <li>VE supplementation in poorly controlled subjects did not improve FBG, HbA<sub>1c</sub>, fructosamine, cholesterol, LDL, HDL, TG, apo-A, apo-B</li> </ul>	<ul style="list-style-type: none"> <li>Form of VE not specified</li> </ul>
70	<ul style="list-style-type: none"> <li>35 type 1</li> <li>Age 12 years</li> </ul>	<ul style="list-style-type: none"> <li>RDBPCT</li> <li>100 IU dl-<math>\alpha</math> VE/day</li> <li>3 months</li> </ul>	<ul style="list-style-type: none"> <li>Modest but significant decrease in HbA<sub>1c</sub>, 12.8 to 11.5% (<math>P &lt; 0.05</math>)</li> <li>Modest but significant decrease in TG (<math>P &lt; 0.03</math>)</li> </ul>	<ul style="list-style-type: none"> <li>Clinical significance of results is low</li> <li>Hematological indices OK</li> </ul>
71	<ul style="list-style-type: none"> <li>25 type 2</li> <li>Italy</li> <li>Age 71 years</li> <li>BMI 27</li> <li>HbA<sub>1c</sub> 7.8%</li> </ul>	<ul style="list-style-type: none"> <li>RDBPCT, crossover</li> <li>900 mg/day d-<math>\alpha</math> VE</li> <li>3 months</li> <li>30-day washout</li> </ul>	<ul style="list-style-type: none"> <li>Decreased FBG (<math>P &lt; 0.05</math>), decreased HbA<sub>1c</sub> 7.8 to 7.1% (<math>P &lt; 0.05</math>)</li> <li>TG (<math>P &lt; 0.02</math>), LDL (<math>P &lt; 0.04</math>), FFA, cholesterol, apo-B (<math>P &lt; 0.05</math>)</li> <li>Supplements increased plasma VE, GSSG/GSH ratio, decreased plasma oxygen production, no effect on fasting or IVGTT insulin</li> </ul>	<ul style="list-style-type: none"> <li>Subjects had no micro- or macrovascular complications</li> <li>Pharmacological dose</li> </ul>
72	<ul style="list-style-type: none"> <li>30</li> <li>Insulin-requiring</li> <li>Age ~41 years</li> <li>BMI ~28</li> <li>HbA<sub>1c</sub> ~11.5%</li> </ul>	<ul style="list-style-type: none"> <li>Group randomized, blinded</li> <li>Placebo 600, 1,200 mg VE/day</li> <li>Groups matched for age, duration, and control of diabetes</li> <li>2 months</li> </ul>	<ul style="list-style-type: none"> <li>Decrease in HbA<sub>1c</sub> 11.8 to 7.8% with 1,200 mg/day (<math>P &lt; 0.01</math>), 11.5 to 8.9% with 600 mg/day (<math>P &lt; 0.001</math>)</li> <li>No change in fasting or mean daily BG level or response to hyperglycemic clamp</li> <li>VE may act in an early step of glycation, possibly glucose auto-oxidation</li> </ul>	<ul style="list-style-type: none"> <li>C-peptide levels mean 0.5–0.6 nmol/l</li> <li>Form of VE not specified</li> <li>Dose-dependent effect of VE on HbA<sub>1c</sub></li> </ul>
67	<ul style="list-style-type: none"> <li>5 type 2</li> <li>10 healthy controls</li> <li>BMI 26</li> <li>OHA</li> <li>HbA<sub>1c</sub> 7.9%</li> </ul>	<ul style="list-style-type: none"> <li>RDBPCT, crossover</li> <li>900 mg/day dl-<math>\alpha</math> VE</li> <li>4 months</li> <li>1-month washout</li> </ul>	<ul style="list-style-type: none"> <li>Diabetes plus VE decreased FBG (<math>P &lt; 0.05</math>) and HbA<sub>1c</sub> 7.9 to 7.0% (<math>P &lt; 0.04</math>)</li> <li>Diabetes plus VE decreased OGTT AUC (<math>P &lt; 0.03</math>) and increased glucose disposal (<math>P &lt; 0.02</math>) and nonoxidative glucose metabolism (<math>P &lt; 0.02</math>)</li> <li>Diabetes plus VE no change in basal or 2 hr OGTT insulin levels</li> <li>VE increased serum VE and improved oxidative and membrane viscosity and to a greater degree in diabetes</li> </ul>	<ul style="list-style-type: none"> <li>dl-<math>\alpha</math> VE</li> <li>Pharmacological dose</li> <li>No side effects noted</li> </ul>
68	<ul style="list-style-type: none"> <li>11 type 2</li> <li>9 healthy controls</li> <li>BMI diabetes 31.6</li> <li>Age ~44 years</li> <li>D, OHA, M</li> </ul>	<ul style="list-style-type: none"> <li>Not randomized, no placebo, not blinded</li> <li>600 mg/day <math>\alpha</math>-VE</li> </ul>	<ul style="list-style-type: none"> <li>VE decreased glucose disposal rate (<math>P &lt; 0.02</math>) and metabolic clearance rate of GL (<math>P &lt; 0.01</math>)</li> <li>Subjects with diabetes had lower serum VE and higher MDA, TPA, and PAI-1</li> <li>VE increased serum VE levels, decreased TPA to control levels, decreased MDA, and resulted in no change in PAI-1</li> </ul>	<ul style="list-style-type: none"> <li>d- versus dl-<math>\alpha</math> VE not specified</li> <li>BMI control 25</li> </ul>

cont'd on page 143

Table 5. Select Vitamin E Clinical Trials *cont'd*

Ref.	Subjects	Design	Results	Notes
75	<ul style="list-style-type: none"> <li>• 2,545 women</li> <li>• 6,996 men</li> <li>• 3,577 diabetes (38%)</li> <li>• 55 years or older</li> <li>• High CVD risk</li> </ul>	<ul style="list-style-type: none"> <li>• RDBPCT 2×2 factorial design</li> <li>• VE 400 IU, 400 IU plus ACE-I, ACE-I</li> <li>• Natural VE</li> <li>• Mean treatment duration 4.5 years</li> </ul>	<ul style="list-style-type: none"> <li>• No change in incidence of MI, stroke, or death from cardiovascular causes, death from all causes, or secondary cardiovascular events in VE-supplemented subjects with or without diabetes</li> <li>• There were no significant adverse effects associated with VE, no increase in hemorrhagic stroke, and no side effects in those on antiplatelet prescription</li> </ul>	<ul style="list-style-type: none"> <li>• Subjects had previous CVD event or CVD risk factor including diabetes</li> <li>• Stopped 6 months early because of the clear benefit of ACE-I</li> </ul>
64	<ul style="list-style-type: none"> <li>• 21 type 2</li> <li>• Age ~61 years</li> <li>• BMI ~29.5</li> <li>• HbA<sub>1c</sub> 6–10%</li> <li>• D and/or OHA</li> </ul>	<ul style="list-style-type: none"> <li>• RDBPCT</li> <li>• 10 weeks</li> <li>• 1,600 IU dl-α VE</li> </ul>	<ul style="list-style-type: none"> <li>• VE supplements increased plasma and LDL (buoyant and dense) VE levels</li> <li>• VE decreased susceptibility of LDL (<math>P &lt; 0.01</math>); protection was greater for buoyant LDL than for dense LDL</li> <li>• No change in glycemic indices or protein glycation including LDL</li> <li>• No changes in lipoprotein levels</li> </ul>	<ul style="list-style-type: none"> <li>• Diet records used to ensure % fat, MUFA, PUFA, VE were similar</li> <li>• Mean HbA<sub>1c</sub> 7–8%</li> <li>• No significant dyslipidemia</li> </ul>

ACE-I, angiotensin-converting enzyme inhibitor; AUC, area under the curve; BG, blood glucose; D, use of medical nutrition or diet therapy; FBG, fasting blood glucose; FFA, free fatty acid; GSSG/GSH, oxidized/reduced glutathione ratio; IMDIAB IV, Immunotherapy of Diabetes Study IV; IVGTT, intravenous glucose tolerance test; M, metformin; MDA, malondialdehyde; MI, myocardial infarction; MUFA, monounsaturated fatty acid; OGTT, oral glucose tolerance test; OHA, oral hypoglycemic agent; PAI-1, tissue plasminogen activator inhibitor 1; PUFA, polyunsaturated fatty acid; RDBPCT, randomized, double-blind, placebo-controlled trial; TG, triglycerides; TPA, tissue plasminogen activator; VE, vitamin E.

(and decreased incidence of ischemic stroke) in smokers.<sup>4</sup> In vitro assays suggest that vitamin E can have some pro-oxidant activity, but this has not been shown in in vivo studies.<sup>4</sup>

**Clinical application.** Good sources of vitamin E are primarily higher-fat foods, such as vegetable oils, margarines, wheat germ, seeds, and nuts.<sup>2</sup> Adequate intakes for antioxidant activity may be difficult to achieve for those following low-fat diets.

Supplements containing natural (d-alpha tocopherol) vitamin E are more bioavailable. Doses may need to be increased as much as two times that of natural vitamin E if the synthetic form of the vitamin (dl-alpha-tocopherol) is used.<sup>4</sup>

Patients using medications such as orlistat, which decrease vitamin E absorption, may require vitamin E supplements. The ADA does not recommend regular supplementation of vitamin E in people with diabetes.<sup>21</sup>

### B Vitamins Involved in Homocysteine Metabolism

Hyperhomocysteinemia (Hhcy) is positively correlated with coronary heart disease, cerebrovascular disease, and peripheral vascular disease.<sup>81</sup> It has not been determined whether the presence of Hhcy precedes or follows vascular diseases.

A recent prospective, population-based study found that Hhcy is a risk

factor for overall mortality in type 2 diabetic patients independent of other known risk factors. Hhcy was a twofold stronger risk factor for death in diabetic patients as compared to nondiabetic patients. For each 5 μmol/l increment of homocysteine, risk of mortality rose by 17% in nondiabetic and 60% in diabetic subjects.<sup>82</sup>

Adequate levels of the vitamins pyridoxine (vitamin B<sub>6</sub>), cobalamin (vitamin B<sub>12</sub>), and folate are necessary for normal homocysteine metabolism.<sup>1</sup> Folate refers to a family of naturally occurring compounds. Folic acid is the synthetic form of the vitamin. Folate is an essential coenzyme for reactions involving the transfer of one-carbon units in amino acid and nucleic acid synthesis.<sup>1,4</sup>

The RDA for folate is 400 μg/day folate equivalents for adults and 600 μg per day in pregnancy. The UL is 1,000 μg/day of folic acid from supplements and does not include dietary sources. Folate is widely available in the food supply but as much as 50–95% of it may be destroyed by processing.<sup>1</sup> Folic acid is the preferred supplemental form.

Conditions that increase the risk of folate deficiency include pregnancy and lactation; alcoholism; anorexia; older age; chronic use of medications such as anticonvulsants, antiproliferative drugs, and oral contraceptives;

malabsorption disorders; and gastrointestinal surgery.<sup>1,4</sup>

The biguanide metformin may reduce folate and vitamin B<sub>12</sub> absorption and increase homocysteine levels.<sup>83,84</sup> The clinical significance of this effect is unknown. Folic acid supplements in patients using metformin decreased homocysteine levels,<sup>85</sup> and calcium supplements improved serum B<sub>12</sub> levels presumably by reversing the negative effects of metformin on vitamin B<sub>12</sub> absorption.<sup>86</sup>

B<sub>12</sub> has been used as a treatment for peripheral neuropathy in diabetes, but there is insufficient evidence to support this use. Many of the symptoms of B<sub>12</sub> deficiency are similar to those associated with aging and neuropathy (ataxia, memory changes).<sup>1</sup> Thus, clinicians must be alert to the possibility of and specifically test for B<sub>12</sub> deficiency in these populations. Risk of vitamin B<sub>12</sub> deficiency is increased with elderly age, achlorhydria, alcohol abuse, long-term gastric acid inhibitors, vegan diet, partial gastrectomy, celiac sprue, and autoimmune disorders including type 1 diabetes, AIDS/HIV, and thyroid disorders.<sup>1,4</sup>

The adult RDA for B<sub>12</sub> is 2.4 μg/day. A UL has not been set, but daily doses up to 100 μg/day have not been associated with toxicity.<sup>4</sup>

Risk of B<sub>6</sub> deficiency is increased with elderly age, alcoholism, high-protein intakes, liver disease, dialysis,

and use of medications such as corticosteroids, penicillamine, anticonvulsants, and isoniazid.<sup>1,4</sup> Poor glycemic control may also lead to increased urinary losses.

B<sub>6</sub> acts as an essential cofactor for hundreds of enzymes and plays a role in glucose, lipid, and amino acid metabolism and neurotransmitter synthesis. The active coenzyme form of the vitamin, pyridoxal 5'phosphate, in muscle tissue is closely associated with glycogen phosphorylase.<sup>1</sup> Deficiency of B<sub>6</sub> in humans and animals is associated with glucose intolerance, but supplementation does not result in improved glycemic control.<sup>2</sup> B<sub>6</sub> is not an effective treatment for diabetic neuropathy.<sup>3</sup> The RDA for B<sub>6</sub> is 1.3 mg/day for adults up to the age 50.

The RDA increases to 1.5 mg/day for women and 1.7 mg/day for men over age 50. The UL for B<sub>6</sub> is 100 mg/day for adults.

**Mechanism of action.** The amino acid homocysteine can be metabolized through transulfuration or remethylation. In the remethylation pathway, methionine synthase converts homocysteine to methionine using folate as the methyl donor.<sup>1,81</sup> B<sub>12</sub> acts as an essential cofactor for this reaction. In the transulfuration pathway, homocysteine and serine combine to form cystathione. This reaction is catalyzed by cystathione B-synthase and requires B<sub>6</sub> as a coenzyme.<sup>1,81</sup>

The mechanism by which increased homocysteine levels increase CVD risk has not been determined but is believed to result from pro-oxidant activity of the amino acid, endothelial dysfunction, and increased platelet activation.<sup>81</sup>

**Evidence-based research.** This summary focuses on folate because it is the primary nutritional determinant of homocysteine levels. The prevalence of Hhcs may vary between 5 and 30% in the general population. Hhcs has been found in type 2 diabetes,<sup>87</sup> and in some,<sup>88</sup> but not all,<sup>89</sup> studies of type 1 diabetes. Differences in renal filtration rates may explain some of the variable results seen in serum homocysteine levels in diabetes; hyperfiltration decreases homocysteine levels, and impaired filtration rates increase homocysteine levels.

Elevated plasma levels of homocysteine have been positively associated with CVD in some studies of people with diabetes.<sup>87,88</sup> Hhcs is also associated with increased incidence of nephropathy, decreased renal func-

tion,<sup>87,88,90</sup> and other microvascular complications of diabetes.<sup>88,90,91</sup> Others have found no association between homocysteine levels and CVD,<sup>90,91</sup> retinopathy,<sup>90</sup> and indices of renal function<sup>92</sup> or neuropathy.<sup>87</sup>

It has not been determined whether the presence of Hhcs precedes or follows the development of these conditions, although impairment of renal function clearly contributes to Hhcs. Elevated homocysteine levels in diabetes have also been associated with menopausal status, increased body mass index, smoking, and age.

In people without diabetes, there is an inverse correlation between serum folate and homocysteine levels, even in subjects with adequate nutrition.<sup>81</sup> In diabetes, serum folate and homocysteine levels have been found to be inversely correlated in some,<sup>87,90</sup> but not all,<sup>89</sup> studies. Serum B<sub>12</sub> levels<sup>90</sup> are also inversely correlated with homocysteine levels, and serum pyridoxal 5'phosphate (B<sub>6</sub>) is inversely correlated with post-methionine-load homocysteine levels.

In patients with diabetes and Hhcs, increased folate intake decreases and in some cases normalizes serum homocysteine levels.<sup>85,93</sup> A meta-analysis found that treatment with 0.5–5 mg/day of folic acid lowers homocysteine levels by 15–40% within 6 weeks.<sup>94</sup> Others have estimated that decreasing homocysteine levels by 5 μmol/l may reduce cardiovascular death by 10%.<sup>95</sup> It is not known if supplementation is effective in prevention or treatment of micro- and macrovascular complications associated with Hhcs.

When evaluating research in this area, one should pay particular attention to the folate, B<sub>12</sub>, and B<sub>6</sub> status of subjects; dose and form of folate used; effects of supplementation on folate and homocysteine levels; subjects' age, type of diabetes, use of biguanides, duration of diabetes, menopausal status, weight, and glycemic control; presence of impaired renal function or hyperfiltration; and length of supplementation, with more than 4 weeks and possibly up to 3 months necessary for full effects. The impact of ethnicity and methylenetetrahydrofolate reductase (MTHFR) gene mutation incidence could also affect results. (MTHFR is an enzyme essential for the metabolism of folate and is important in the metabolism of homocysteine. A common mutation

in the MTHFR gene is associated with Hhcs in homozygous subjects.)

**Side effects and contraindications.** Doses of folate ≤15 mg/day have not been associated with adverse effects in healthy adults.<sup>4</sup> However, folate supplementation may mask the anemia associated with B<sub>12</sub> deficiency and result in permanent nerve damage.<sup>1</sup> High-dose folate supplements may also interfere with anticonvulsant medications.<sup>1</sup> High-dose B<sub>6</sub> supplements are not recommended as a treatment for neuropathy; in fact, toxicity symptoms include neuropathy.<sup>2</sup>

**Clinical application.** Long-term trials are needed to determine the effects of folic acid on micro- and macrovascular complications, both early and late in the disease process. Early research suggests that folate supplements decrease Hhcs levels and may be beneficial in the prevention and management of vascular complications in diabetes. Folic acid supplements are recommended for all women of childbearing age.

The primary risk of supplementation relates to the potential for undiagnosed B<sub>12</sub> deficiency. Since impaired B<sub>12</sub> absorption is estimated to occur in 10–30% of people over the age of 50, assessment of B<sub>12</sub> status in patients with peripheral neuropathy is prudent. In elderly people with achlorhydria, synthetic forms of oral B<sub>12</sub> supplements are better absorbed than food-bound B<sub>12</sub> and are therefore preferred. The use of biguanides may decrease folate and B<sub>12</sub> absorption.

All patients with diabetes should be encouraged to consume adequate quantities of dietary folate, B<sub>12</sub>, and B<sub>6</sub> and to modify factors such as alcohol intake and smoking, which increase homocysteine levels. All "enriched" cereal grain products (rice, flour, breakfast cereals, pasta, bread) in the United States have been fortified with folic acid since 1998. Good dietary sources of folate include fortified grain and cereal products, spinach, orange juice, strawberries, and peanuts.<sup>4</sup> Good dietary sources of B<sub>12</sub> are animal products, and good sources of B<sub>6</sub> include whole grains, animal products, and legumes.<sup>4</sup>

## SUMMARY

As health care providers interested in promoting the optimal health of people with diabetes, we need to act as an unbiased resource on the numerous

treatments available to our patients. We need to be open to new treatment regimens while also serving as careful watchdogs for ineffective or dangerous therapies. Above all, we need to encourage our patients' involvement in and ownership of their diabetes, and help them to focus their efforts where they are likely to receive the greatest benefits. In the future, this will likely include nutritional supplements for people whom research has identified as having the genetic or clinical potential to benefit from them.

## References

- <sup>1</sup>Shils ME, Olson JA, Shike M, Ross AC, Eds.: *Modern Nutrition in Health and Disease*. 9th edition. Philadelphia Pa., Lea & Febiger, 1999
- <sup>2</sup>Franz MJ, Bantle JP, Eds.: *American Diabetes Association Guide to Medical Nutrition Therapy for Diabetes*. Alexandria Va., American Diabetes Association, 1999
- <sup>3</sup>Mooradian AD, Failla M, Hoogwerf B, Marynuik M, Wylie-Rosett J. Selected vitamins and minerals in diabetes. *Diabetes Care* 17:464-479, 1994
- <sup>4</sup>Sarubin A: *The Health Professional's Guide to Popular Dietary Supplements*. Chicago, The American Dietetic Association, 2000
- <sup>5</sup>Anderson RA: Chromium, glucose intolerance and diabetes. *J Am Col Nutr* 17:548-555, 1998
- <sup>6</sup>Mertz W: Interaction of chromium with insulin: a progress report. *Nutr Rev* 56:174-177, 1998
- <sup>7</sup>Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, Feng J: Beneficial effects of chromium for people with diabetes. *Diabetes* 46:1786-1791, 1997
- <sup>8</sup>Ravina A, Slezak L, Rubal A, Mirsky N: Clinical use of trace element chromium (III) in the treatment of diabetes mellitus. *J Trace Elem Exp Med* 8:183-1190, 1995
- <sup>9</sup>Lee NA, Reasner CA: Beneficial effect of chromium supplementation on serum triglycerides in NIDDM. *Diabetes Care* 17:1449-1452, 1994
- <sup>10</sup>Abraham AS, Brooks BA, Eylal U: The effect of chromium supplementation on serum glucose and lipids in patients with non-insulin-dependent diabetes mellitus. *Metab Clin Exp* 41:768-771, 1992
- <sup>11</sup>Cefalu WT, Bell-Farrow AD, Stegner J, Wang ZQ, King T, Morgan, Terry JG: Effect of chromium picolinate on insulin sensitivity in vivo. *J Trace Elem Exp Med* 12:71-83, 1999
- <sup>12</sup>Cheng N, Zhu X, Shi H, Wu W, Chi J, Cheng J, Anderson RA: Follow-up survey of people in China with type 2 diabetes mellitus consuming supplemental chromium. *J Trace Elem Exp Med* 12:55-60, 1999
- <sup>13</sup>Trow LG, Lewis J, Greenwood RH, Sampson MJ, Self KA, Crews HM, Fairweather-Tait SJ: Lack of effect of dietary chromium supplementation on glucose tolerance, plasma insulin and lipoprotein levels in patients with type 2 diabetes. *Int J Vitam Nutr Res* 70:14-18, 2000
- <sup>14</sup>Jovanovic L, Gutierrez M, Peterson CM: Chromium supplementation for women with gestational diabetes mellitus. *J Trace Elem Exp Med* 12:91-97, 1999
- <sup>15</sup>Anderson RA, Polansky MM, Bryden NA, Canary JJ: Supplemental-chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled-low-chromium diets. *Am J Clin Nutr* 54:909-916, 1991
- <sup>16</sup>Anderson RA, Polansky MM, Bryden NA, Bhatena SJ, Canary JJ: Effects of supplemental chromium on patients with symptoms of reactive hypoglycemia. *Metabolism* 36:351-355, 1987
- <sup>17</sup>Uusitupa MI, Mykkanen L, Siitonen O, Laakso M, Sarlund H, Kolehmainen P, Rasanen T, Kumpulainen J, Pyorala K: Chromium supplementation in impaired glucose tolerance of elderly: effects on blood glucose, plasma insulin, C-peptide and lipid levels. *Br J Nutr* 68:209-216, 1992
- <sup>18</sup>Ravina A, Slezak L, Mirsky N, Bryden NP, Anderson RA: Reversal of corticosteroid-induced diabetes with supplemental chromium. *Diabet Med* 16:164-167, 1999
- <sup>19</sup>Stearns DM: Is chromium a trace essential element? *BioFactors* 11:149-162, 2000
- <sup>20</sup>McWhorter L, Geil PB: Biological complementary therapies in diabetes. In *A Core Curriculum for Diabetes Educators*. 4th edition. Franz MJ, Kulkarni K, Polansky WH, Yarborough PC, Zamudio V, Eds. Chicago, American Association of Diabetes Educators. In press
- <sup>21</sup>Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson J-L, Garg A, Holzmeister LA, Hoogwerf B, Purnell JQ, Wheeler ML: Evidence-based nutrition recommendations for diabetes and related complications (Technical review). *Diabetes Care*. In press
- <sup>22</sup>Harland BF, Harden-Williams BA: Is vanadium of nutritional importance yet? *J Am Diet Assoc* 94:891-894, 1994
- <sup>23</sup>Poucheret P, Verma S, Grynepas MD, McNeil JH: Vanadium and diabetes. *Mol Cell Biol* 188:73-80, 1998
- <sup>24</sup>Cam MC, Brownsey RW, McNeil JH: Mechanisms of vanadium action: insulin mimetic or insulin-enhancing agent? *Can J Physiol Pharmacol* 78:829-847, 2000
- <sup>25</sup>Goldfine A, Simonson D, Folli F, Patti ME, Kahn R: Metabolic effects of sodium metavanadate in humans with insulin-dependent and non-insulin dependent diabetes mellitus in vivo and in vitro studies. *J Clin Endocrinol Metab* 80:3311-3320, 1995
- <sup>26</sup>Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H: Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not obese nondiabetic subjects. *Diabetes* 45:659-666, 1996
- <sup>27</sup>Cohen N, Halberstam M, Schilmovich P, Chang CJ, Shamoon H, Rossetti L: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin dependent diabetes mellitus. *J Clin Invest* 95:2501-2509, 1995
- <sup>28</sup>Boden G, Chen X, Ruiz J, van Rossum GD, Turco S: Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin dependent diabetes mellitus. *Metabolism* 45:1130-1135, 1996
- <sup>29</sup>Greenbaum CJ, Kahn SE, Palmer JP: Nicotinamides effects on glucose metabolism in subjects at risk for IDDM. *Diabetes* 45:1631-1634, 1996
- <sup>30</sup>Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, Kolb H, and the DENIS group: The Deutsch Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. *Diabetes* 47:980-984, 1998
- <sup>31</sup>Elliott RB, Pilcher CC, Fergusson DM, Stewart AW: A population-based strategy to prevent insulin-dependent diabetes using nicotinamide. *J Pediatr Endocrinol Metab* 9:501-509, 1996
- <sup>32</sup>Gale EAM: Nicotinamide: potential for the prevention of type 1 diabetes? *Horm Metab Res* 28:361-364, 1996
- <sup>33</sup>Pozzilli P, Browne PD, Kolb H, The Nicotinamide Trialists: Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. *Diabetes Care* 19:1357-1363, 1996
- <sup>34</sup>Pozzilli P, Vissali N, Girhlanda G, Manna R, Andreani D: Nicotinamide increases C-peptide secretion in patients with recent onset type 1 diabetes. *Diabet Med* 6:568-572, 1989
- <sup>35</sup>Pozzilli P, Vissali N, Signore A, Baroni MG, Buzzetti R, Cavallo MG, Boccini ML, Fava D, Gragnoli C, Andreani D, Lucentini L, Mattwoli MC, Crino A, Cicconetti CA, Teodonio C, Paci F, Amoretti R, Pisano L, Pennafina MG, Santopadre G, Marozzi G, Multari G, Suppa MA, Campea L, DeMattia GC, Cassone M, Faldetta G, Marietti G, Perrone F, Greco AV, Ghirlanda G: Double-blind trial of nicotinamide in recent onset IDDM (the IMDIAB III study). *Diabetologia* 38:848-852, 1995
- <sup>36</sup>Vissali N, Cavallo MG, Signore A, Baroni MG, Buzzetti R, Fioriti E, Mesturino C, Fiori R, Lucentini L, Matteoli MC, Crino A, Corbi S, Spera S, Teodonio C, Paci F, Amoretti R, Pisano L, Suraci C, Multari G, Sulli N, Cervoni M, DeMattia G, Faldetta MR, Boscherini B, Biti MLM, Marietti G, Ferrazzoli F, Bizzarri C, Pitocco D, Ghirlanda G, Pozzilli P: A multi-center, randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI). *Diabetes Metab Res Rev* 15:181-185, 1999
- <sup>37</sup>Polo V, Saibene A, Pontiroli AE: Nicotinamide improves insulin secretion and metabolic control in lean type 2 patients with secondary failure to sulphonylureas. *Acta Diabetol* 35:61-64, 1998
- <sup>38</sup>Kolb H, Volker B: Nicotinamide in type 1 diabetes mechanism of action revisited. *Diabetes Care* 22 (Suppl. 2):B16-B20, 1999
- <sup>39</sup>Knip M, Douek IF, Moore WPT, Gillmor HA, McLean AEM, Bingley PJ, Gale EAM, for the ENDIT Group: Safety of high-dose nicotinamide: a review. *Diabetologia* 43:1337-1345, 2000
- <sup>40</sup>de Valk H: Magnesium in diabetes mellitus. *J Med* 54:139-146, 1999
- <sup>41</sup>American Diabetes Association: Magnesium supplementation in the treatment of diabetes (Consensus statement). *Diabetes Care* 15:1065-1067, 1992
- <sup>42</sup>Sjogren A, Floren C-H, Nilsson A: Magnesium deficiency in IDDM related to level of glycosylated hemoglobin in diabetes. *Diabetes* 35:459-463, 1986

- <sup>43</sup>de Valk HW, Stuyvenberg A, van Rijn HJM, Haalboom JRE: Plasma magnesium in patients with type 2 (non-insulin dependent) diabetes and non-diabetics attending an outpatient clinic for internal medicine. *Clin Chem Enzyme Comm* 5:151-155, 1993
- <sup>44</sup>Lima DLM, Cruz T, Pousada JC, Rodrigues LE, Barbarosa K, Cangucu V: The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. *Diabetes Care* 21:682-686, 1998
- <sup>45</sup>Eibl NL, Kopp HP, Nowak HR, Schnack CJ, Hopmeier PG, Schernthaner G: Hypomagnesemia in type II diabetes: effect of a 3-month replacement therapy. *Diabetes Care* 18:188-192, 1995
- <sup>46</sup>Meyer KA, Kushi LH, Jacobs DR, Slavin J, Sellers TA, Folsom AR: Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. *Am J Clin Nutr* 71:921-930, 2000
- <sup>47</sup>Kao WHL, Folsom AR, Nieto FJ, Mo J-P, Watson RL, Brancati FL: Serum and dietary magnesium and the risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities (ARIC) Study. *Arch Intern Med* 159:2151-2159, 1999
- <sup>48</sup>Schmidt L, Heins J: Low magnesium intake among NIDDM patients: a call for concern (Abstract). *Diabetes* 42 (Suppl. 1):A49, 1993
- <sup>49</sup>Paolisso G, Sgambato S, Pizza G, Passariello N, Varricchio M, D'Onofrio F: Improved insulin response and action by chronic magnesium administration in aged NIDDM subjects. *Diabetes Care* 12:265-269, 1989
- <sup>50</sup>Gullestad L, Jacobsen T, Dolva LO: Effect of magnesium treatment on glycemic control and metabolic parameters in NIDDM patients. *Diabetes Care* 17:460-461, 1994
- <sup>51</sup>de Valk HW, Verkaaik R, van Rijn HJM, Geerdink RA, Struyvenberg A: Oral magnesium supplementation in insulin-requiring type 2 patients. *Diabet Med* 15:503-507, 1998
- <sup>52</sup>Ma J, Folsom AR, Melnick SL, Eckfeldt JH, Sharrett AR, Nabulsi AA, Hutchinson RG, Metcalf PA: Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness in the ARIC study. *J Clin Epidemiol* 48:927-940, 1995
- <sup>53</sup>Paolisso G, Scheen A, Cozzolino D, Di Maro G, Varricchio M, D'Onofrio F, Lefebvre PJ: Changes in glucose turnover parameters and improvement of glucose oxidation after 4-week magnesium administration in elderly noninsulin-dependent (type 2) diabetic patients. *J Clin Endocrinol Metab* 78:1510-1514, 1994
- <sup>54</sup>Whelton P, Klag M: Magnesium and blood pressure: a review of the epidemiological and clinical trial experience. *Am J Cardiol* 63:26G-30G, 1989
- <sup>55</sup>Djorhus MS, Henriksen JE, Klitgaard NAH, Blaabjerg O, Thyse-Ronn P, Altura B, Altura BT, Beck-Neilsen H: Effect of moderate improvement of metabolic control on magnesium and lipid concentrations in patients with type 1 diabetes. *Diabetes Care* 22:546-554, 1999
- <sup>56</sup>Walter RM, Uriu-Hare JY, Olin KL, Oster MH, Anawalt BD, Critchfield JW, Keen CL: Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus. *Diabetes Care* 14:1050-1056, 1991
- <sup>57</sup>Corsonello A, Lentile R, Buemi M, Cucinotta D, Mauro VN, Macaione S, Corica F: Serum ionized magnesium levels in type 2 diabetic patients with microalbuminuria or clinical proteinuria. *Am J Nephrol* 20:187-192, 2000
- <sup>58</sup>Salonen JT, Nyyssonen K, Tuomainen TP, Maenpaa PH, Korpela H, Kaplan GA, Lynch J, Helmrich SP, Salonen R: Increased risk of non-insulin-dependent diabetes mellitus at low plasma vitamin E concentrations: a four-year study in men. *BMJ* 311:1124-1127, 1995
- <sup>59</sup>Polidori MC, Mecocci P, Stahl W, Parente B, Cecchetti R, Cherubini A, Cao P, Sies H, Senin U: Plasma levels of lipophilic antioxidants in very old patients with type 2 diabetes. *Diabetes Metab Res Rev* 16:15-19, 2000
- <sup>60</sup>Sharma A, Kharb S, Chugh SN, Kakkar R, Singh GP: Evaluation of oxidative stress before and after control of glycemia and after vitamin E supplementation in diabetic patients. *Metabolism* 49:160-162, 2000
- <sup>61</sup>Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A, Tonutti L, Taboga C: Meal-generated oxidative stress in type 2 patients. *Diabetes Care* 21:1529-1533, 1998
- <sup>62</sup>Santini SA, Marra G, Giardina B, Cottroneo P, Mordente A, Martorana GE, Manto A, Ghirlanda G: Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. *Diabetes* 46:1853-1858, 1997
- <sup>63</sup>Ceriello A, Bortolotti N, Falleti E, Taboga C, Tonutti L, Crescentini A, Motz E, Lizzio S, Russo A, Bartoli E: Total radical-trapping antioxidant parameter in non-insulin dependent diabetic patients. *Diabetes Care* 20:194-197, 1997
- <sup>64</sup>Reaven PD, Herold DA, Barnett J, Edelman S: Effects of vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM. *Diabetes Care* 18:807-816, 1995
- <sup>65</sup>Devaraj S, Jialal I: Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications. *Circulation* 102:191-196, 2000
- <sup>66</sup>Pozzoli P, Vissali N, Cavallo MG, Signore A, Baroni MG, Buzzetti R, Fioriti E, Mesturino C, Fiori R, Romiti A, Giovannini C, Lucentini L, Matteoli MC, Crino A, Teodonio C, Paci F, Amoretti R, Pisano L, Suraci MT, Multari G, Suppa M, Sulli N, De Mattia G, Faldetta MRC, Boscherini B, Stoduto S, Fonte MT, Bitti MLM, Marietta G, Ferrazzoli F, Greco AV, Ghirlanda G: Vitamin E and nicotinamide have similar effects in maintaining residual  $\beta$  cell function in recent onset insulin-dependent diabetes (The IMDIAB IV study). *Eur J Endocrinol* 137:234-239, 1997
- <sup>67</sup>Paolisso G, D'Amore A, Giugliano D, Cereillo A, Varricchio M, D'Onofrio F: Pharmacological doses of vitamin E improve insulin action in healthy subjects and non-insulin dependent diabetic patients. *Am J Clin Nutr* 57:650-656, 1993
- <sup>68</sup>Skrha J, Sindelka G, Kvasnicka J, Hilgertova J: Insulin action and fibrinolysis influenced by vitamin E in obese type 2 diabetes mellitus. *Diab Res Clin Pract* 4:27-33, 1999
- <sup>69</sup>Gomez-Perez FJ, Valles-Sanchez VE, Lopez-Alvarenga JC, Pascual JJI, Orellana RG, Padilla OBP, Salinas EGR, Rull JA: Vitamin E modifies neither fructosamine nor HbA<sub>1c</sub> levels in poorly controlled diabetes. *Rev Invest Clin* 48:421-424, 1996
- <sup>70</sup>Jain SK, McVie R, Jaramillo JJ, Palmer M, Smith T: Effect of modest vitamin E supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in type 1 diabetic patients. *J Am Coll Nutr* 15:458-461, 1996
- <sup>71</sup>Paolisso G, D'Amore A, Galzerano D, Balbi V, Giugliano D, Varricchio M, D'Onofrio F: Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type 2 diabetic patients. *Diabetes Care* 16:1433-1437, 1993
- <sup>72</sup>Cerillo A, Giugliano D, Quataro A, Donzella C, Dipalo G, Lefebvre PJ: Vitamin E reduction of protein glycosylation in diabetes. *Diabetes Care* 14:68-72, 1991
- <sup>73</sup>Tutuncu NB, Bayraktar N, Varli K: Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes. *Diabetes Care* 21:1915-1918, 1998
- <sup>74</sup>Bursell SE, Clermont AC, Aiello LP, Aiello LM, Schlossman DK, Feener EP, Laffel L, King GL: High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. *Diabetes Care* 22:1245-1251, 1999
- <sup>75</sup>Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study. *N Engl J Med* 342:154-160, 2000
- <sup>76</sup>Andrew R, Skyrme-Jones P, O'Brien RC, Berry KL, Meredith IT: Vitamin E supplementation improves endothelial function in type 1 diabetes mellitus: a randomized, placebo-controlled study. *J Am Coll Cardiol* 36:94-102, 2000
- <sup>77</sup>Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC: Vitamin E consumption and the risk of coronary heart disease in men. *N Engl J Med* 328:1450-1456, 1993
- <sup>78</sup>Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC: Vitamin E consumption and the risk of coronary disease in women. *N Engl J Med* 328:1444-1449, 1993
- <sup>79</sup>Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ: Randomized, controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. *Lancet* 347:781-786, 1996
- <sup>80</sup>Jain SK: Should high-dose vitamin E supplementation be recommended to diabetic patients? *Diabetes Care* 22:1242-1244, 1999
- <sup>81</sup>Welch GN, Loscalzo J: Homocysteine and atherothrombosis. *New Engl J Med* 338:1042-1050, 1998
- <sup>82</sup>Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA: Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5 year follow-up of the Hoorn study. *Circulation* 101:1506-1511, 2000
- <sup>83</sup>Lee JL: Metformin in noninsulin-dependent diabetes mellitus. *Pharmacotherapy* 16:327-351, 1996
- <sup>84</sup>Carlsen SM, Folling I, Grill V, Bjerke KS,

- Schneede J, Refsum H: Metformin increases total homocysteine levels in nondiabetic male patients with coronary heart disease. *Scand J Clin Invest* 57:521–528, 1997
- <sup>85</sup>Aarsand AK, Carlsen SM: Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. *J Intern Med* 244:169–174, 1998
- <sup>86</sup>Bauman WA, Shaw S, Jayatilleke E, Spungen AM, Herbert V: Increased intake of calcium reverses vitamin B<sub>12</sub> malabsorption induced by metformin. *Diabetes Care* 23:1227–1231, 2000
- <sup>87</sup>Busyschaert M, Dramais AS, Wallemacq PE, Hermans MP: Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. *Diabetes Care* 23:1816–1822, 2000
- <sup>88</sup>Hofman MA, Kohl B, Zumbrach MS, Borcea V, Bierhaus A, Henkels M, Amiral J, Schmidt AM, Fiehn W, Ziegler R, Wahl P, Nawroth PP: Hyperhomocysteinemia and endothelial dysfunction in IDDM. *Diabetes Care* 21:841–848, 1998
- <sup>89</sup>Salardi S, Cacciari E, Sassi S, Grossi G, Mainetti B, Casa CD, Pirazzoli P, Cicognani A, Gualandi S: Homocysteinemia, serum folate and vitamin B<sub>12</sub> in very young patients with diabetes mellitus type 1. *J Pediatr Endocrinol Metab* 13:1621–1627, 2000
- <sup>90</sup>Stabler SP, Estacio R, Jeffers BW, Cohen JA, Allen RH, Schrier RW: Total homocysteine is associated with neuropathy in non-insulin dependent diabetes mellitus. *Metabolism* 48:1096–1101, 1999
- <sup>91</sup>Abdella N, Mojiminiyi OA, Akanji AO: Homocysteine and endogenous markers of renal function in type 2 diabetic patients without coronary heart disease. *Diabetes Res Clin Pract* 50:177–185, 2000
- <sup>92</sup>Hoogeveen EK, Kostense PJ, Eysink PED, Polak BCP, Beks PJ, Jakob C, Dekker J, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. *Arch Intern Med* 160:2984–2990, 2000
- <sup>93</sup>Baliga BS, Reynolds T, Fink LM, Fonesca VA: Hyperhomocysteinemia in type 2 diabetes mellitus: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine. *Endocrinol Pract* 6:435–441, 2000
- <sup>94</sup>Chait A, Malinow MR, Nevin D, Morris CD, Eastgard RL, Kris-Etherton P, Pi-Sunyer FX, Oparil S, Resnick L, Stern JS, Haynes RB, Hatton DC, Metz JA, Clark S, McMahon M, Holcomb S, Reusser ME, Snyder GW, McCarron DA: Increased dietary micronutrients decrease serum homocysteine concentrations in patients at high risk of cardiovascular disease. *Am J Clin Nutr* 70:881–887, 1999
- <sup>95</sup>Homocysteine Lowering Trialists' Collaboration: Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. *BMJ* 316:894–898, 1998

---

*Belinda S. O'Connell, MS, RD, LD, is a diabetes nutrition specialist at the International Diabetes Center in Minneapolis, Minn.*